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ABSTRACT OF THE DISSERTATION
FACTORS OF INFLAMMATION IN HAITIAN AMERICANS AND AFRICAN
AMERICANS WITH AND WITHOUT TYPE 2 DIABETES
by
Janet Antwi
Florida International University, 2014
Miami, Florida
Professor Fatma G. Huffman, Major Professor
Chronic low-grade inflammation has been implicated in the processes leading to
the development of type 2 diabetes (T2D) and its progression. Non-Hispanic Blacks bear
a disproportionate burden of T2D and are highly susceptible to inflammation. This crosssectional study assessed and compared the serum levels of established adipocytokines;
interleukin-6 (IL-6), C-reactive protein (CRP), leptin, and novel adipocytokines;
chemerin and omentin in Haitian and African Americans with and without T2D. The
relationships of these adipocytokines with metabolic syndrome (MetS), anthropometric
and HOMA2 measures by ethnicity and diabetes status were also assessed. Serum levels
of IL-6, CRP, leptin, chemerin and omentin were determined by the ELISA method.
HOMA2 measures were calculated for insulin sensitivity (HOMA2-IS) and insulin
resistance (HOMA2-IR).
Analyses of available data for 230 Haitian Americans and 241 African Americans
(240 with and 231 without T2D) for the first study showed that Haitian Americans with
and without MetS had lower levels of IL-6 and CRP compared to African Americans
with and without MetS (P<0.05). MetS was found to be associated with CRP (β = 0.34, P
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= 0.012), but not with IL-6. In the second study (n = 429), Haitian Americans with T2D
had significantly lower serum chemerin levels (P <0.001) and higher serum omentin
levels (P = 0.023) compared to African Americans with T2D. Diabetes status was
negatively associated with chemerin (B = -41.35, P = 0.024), but not associated with
omentin (B = -85.02, P = 0.136). HOMA2-IS was inversely associated with chemerin (B
= -0.229, P = 0.030). Leptin levels in the third study (n= 413) were lower in Haitian
American males and females than African American males and females, regardless of
diabetes status (P<0.05). Leptin levels were significantly associated with BMI (P<0.001)
and HOMA2-IR (P=0.015) in males without T2D.
Ethnic-specific diabetes intervention and treatment programs must be designed to
target Haitian Americans and African Americans as separate unique groups, in order to
reduce the burden of T2D among the non-Hispanic Black community. Further research is
needed to gain better understanding of the role of inflammation and T2D in this
population.
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CHAPTER I: INTRODUCTION
Type 2 diabetes (T2D) is a major public health concern among ethnic minority
groups in the United States and non-Hispanic Blacks in particular, are disproportionately
affected.1-3 The disparities in the incidence and prevalence of T2D among non-Hispanic
Blacks are estimated to be 2 to 6 times of that observed in Caucasians.2,4 While reasons
for these disparities have not been fully understood, increased prevalence of disease risk
factors among this population are considered as the cause.5-6 One such risk factor which
is receiving increased attention is inflammatory processes, since T2D is considered to be
a state of chronic low-grade inflammation.7
Chronic low-grade inflammation, as characterized by increased circulating levels
of pro-inflammatory adipocytokines, is a key feature of chronic diseases including
obesity, T2D and cardiovascular diseases (CVD).8-10 Several studies have associated
plasma levels of pro-inflammatory adipocytokines such as tumor necrosis factor-α (TNFα), interleukin-6 (IL-6), C reactive protein (CRP) and leptin with metabolic risk factors
such as obesity and insulin resistance.13-14 The levels of the anti-inflammatory
adipocytokine, adiponectin are however reduced in these disease conditions.15-17 Similar
observations have also been made between these markers and metabolic syndrome
(MetS) in individuals with and without T2D.8,18
Previous studies that found an association between inflammation and the
pathogenesis and progression of T2D also reported on ethnic differences in the levels of
established adipocytokines such as, TNF-α, IL-6, CRP, leptin and adiponectin.5-6,19
Chemerin and omentin are recently identified novel adipocytokines that have been shown
to have reciprocal effects in inflammatory processes and chronic disorders.20-22 The levels
1

of pro-inflammatory chemerin are increased in obesity, insulin resistance, metabolic
syndrome, T2D and cardiovascular diseases, while the anti-inflammatory omentin is
down-regulated in these disorders.23-27
In a recent study, BMI, fasting serum insulin, triglycerides and high density
lipoprotein cholesterol (HDL-C) were significantly correlated with plasma chemerin
levels in 969 Mexican-Americans with T2D compared to 173 without T2D.28 Similar
relationships have been observed in various other populations.23,29 However, the roles of
chemerin and omentin as novel candidates to link inflammation with T2D in other ethnic
minority subgroups such as Haitian and African Americans have not been studied.
Furthermore, recent studies have associated chemerin and omentin with several
established pro-inflammatory and anti-inflammatory adipocytokines,24,26 but data on their
interactions among Haitian and African Americans is scarce. The study of novel
adipocytokines may provide better understanding of the disparities in T2D that exist
among non-Hispanic Blacks.
Therefore, the aims of this study were to characterize adipocytokines in Haitian
and African Americans with and without T2D and determine the relationships of these
adipocytokines with metabolic syndrome (MetS), anthropometric and HOMA2 measures
by ethnicity and diabetes status controlling for socio-demographic variables, dietary and
lifestyle factors and other health status variables.
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CHAPTER II: LITERATURE REVIEW
Diabetes is a metabolic disorder that has emerged as a global epidemic and is
estimated to be the seventh leading cause of death by the year 2030.1 According to
estimates by the World Health Organization, as of 2011, there were approximately 347
million people with diabetes worldwide.1 In the United States, an estimated 29 million
people have diabetes, of which 90-95% of cases are attributed to type 2 diabetes (T2D).2
The burden of T2D is increasing in parallel to increasing cases of obesity and metabolic
syndrome (MetS).3 Clinical data show that of the people diagnosed with T2D, about 8090% are highly likely to be diagnosed as obese.4 Mozumdar and Liguori3 compared the
National Health and Nutrition Examination Survey (NHANES) data from 1988-1994 and
1999-2006 and revealed that there was a 5% increase in MetS prevalence among US
adults between the two periods. The authors also reported that Mexican-Americans had
the highest prevalence of MetS and there was a significant increase in prevalence among
non-Hispanic Blacks compared with non-Hispanic Whites.
Non-Hispanic Blacks are particularly at a greater risk of T2D and its
complications compared to Hispanics and Non-Hispanic Whites.5-8 Apart from higher
prevalence rates of T2D, ethnic minority groups also have poorer diabetes control and
worse diabetes-related complications. Lanting et al.7 examined ethnic differences in
quality of care, end-stage complications and mortality among patients with diabetes. The
results showed that non-Hispanic Blacks and Hispanics have 2 to 4 times the rate of
blindness, kidney disease and amputation-related mortality of non-Hispanic Whites.
Diabetes data and trends for 2010, available at the Centers for Disease Control and
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Prevention indicated that diabetes-related heart disease and myocardial infarction was
34% in non-Hispanic Blacks, 24.7% in Hispanics and 32.9% in non-Hispanic Whites.5
Compelling evidence from recent studies suggest that observed ethnic differences
in inflammation may provide major explanation to the disparities in T2D prevalence and
health outcomes.9-11 Various analyses of the association between ethnicity and
inflammation showed that non-Hispanic Blacks have higher IL-6 and CRP than
Hispanics and non-Hispanic Whites. Further, TNF-α levels were higher among nonHispanic Blacks compared to non-Hispanic Whites.12 There is the need to understand the
molecular mechanisms that underlie inflammatory processes to relate to their pathogenic
role in metabolic disease development in order to establish strategies to effectively
combat T2D and its complications among non-Hispanic Blacks.
Chronic Low-grade Inflammation
Inflammation is a complex defense mechanism induced by the body to various
injuries and foreign stimuli.13-15 The process of inflammation is a normal immune
response, which may be innate or adaptive. This often self-regulatory and short-term
response is a crucial part of tissue repair and involves the combination of several complex
signals in particular cells and organs.15 The presence of an injury or stimuli initiates the
migration of leucocytes (mainly neutrophils) from circulation into the affected tissues to
attack the agents that possibly can cause tissue injury.14,16 Neutrophils secrete proinflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and interleukin-6
(IL-6) to induce an immune response and return the body to a homeostatic state.17-19
Additionally, IL-6 in particular, stimulates production of the acute-phase reactant, C-
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reactive protein (CRP) from the liver.20-21 This form of inflammatory response referred to
as acute inflammation is actively terminated within the first few hours of inflammatory
response.22 The resolution of inflammation involves mainly eliminating neutrophils by
the phagocytic and destructive actions of monocytes and macrophages and also through
the release of anti-inflammatory cytokines such as IL-10.22-23 Thus, acute inflammation is
considered as a limited, often beneficial response. However, in the presence of an
ongoing stimuli, the immune response may be persistently triggered and lead to chronic
low-grade inflammation.
Chronic low-grade inflammation, in contrast to acute inflammation is associated
with infiltration of mainly monocytes and macrophages of the immune response.14,16
Chronic low-grade inflammation is considered as a chronic activation of the innate
immune system than the adaptive.24 The mechanisms that control the transition from
neutrophil to monocyte/macrophage recruitment during the transformation from acute to
chronic inflammation is poorly understood. However, the body’s own process used to
resolve inflammation, whereby monocytes/macrophages or fibroblasts are recruited to
phagocytize neutrophils has been implicated.22,25 A disruption in control of neutrophils
trafficking by a continuous stimuli, may cause the resolution phase to be disordered. This
may be significant at increased recruitment of monocytes/macrophages and the
overproduction of pro-inflammatory cytokines resulting in a perpetual pro-inflammatory
state.22,25 The long-term consequences of this prolonged inflammation which favors the
production of pro-inflammatory cytokines and decreased levels of anti-inflammatory
cytokines are often detrimental.26-32 The hallmark of chronic low-grade inflammation is
systemic inflammation, which is the involvement of the endothelial, circulatory,
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lymphatic and other organs systems, rather than restricted to a specific tissue. As a result,
chronic low-grade inflammation is characterized by 2 to 3 fold increase in circulating
levels of TNF-α, IL-6 and CRP and decreased levels of IL-10.26 The altered circulating
levels of these pro- and anti-inflammatory cytokines have been observed in various
chronic diseases and it is suggested that chronic low-grade inflammation may be crucial
in the pathogenesis and progression of chronic diseases.26-32 For example, the levels of
circulating TNF-α, IL-6 and CRP have consistently correlated with obesity and insulin
resistance and has provided the basis for an intense area of research into other metabolic
disorders such as metabolic syndrome, type 2 diabetes and cardiovascular diseases.33-34
The discovery of the adipose tissue as an endocrine organ is expected to provide better
insight into the processes underlying the onset and progression of these metabolic
conditions.
Adipose Tissue as a Major Source of Adipocytokines
For many decades, adipose tissue was considered as a fat storage organ and also
known to possess thermogenic properties. In human and animal models, brown adipose
tissue has been shown to be responsible for thermogenesis, whereas white adipose tissue
plays the essential role of being a fat storage site.35 Recently, however, adipose tissue has
been established as an active endocrine organ that produces several bioactive molecules
collectively termed adipocytokines.36-40 They are so named because they are cytokines
produced by the adipose tissue. The most abundant sites are visceral and subcutaneous
adipose tissues,41 which produce bonafide adipocytokines such as leptin and adiponectin
known to elicit pro-inflammatory and anti-inflammatory responses, respectively.42-43

10

Adipocytokines have diverse autocrine, panacrine and endocrine functions and as such
are crucial mediators of metabolic processes including glucose and lipid homeostasis.41-42
For example, leptin and adiponectin have the ability to cross the blood-brain barrier and
reach their main site of action in the hypothalamus to regulate the balance of hunger and
satiety.38 Thus, these adipocytokines play a major role in the control of energy
metabolism, the nutrient status of the organism and energy expenditure.44 Several
investigations have also highlighted the importance of TNF-α and IL-6, as
adipocytokines which activate inflammatory signaling cascades in adipose tissue.33-34 The
adipose tissue is known to produce about 10-35% of the body’s IL-6 levels.45 Moreover,
in a recent in vivo study, human adipocyte cell lines were found to have the capacity to
also produce CRP.46 It is important to know the initiating factors responsible for
induction of adipose tissue inflammation and the mechanism that continue to amplify the
pro-inflammatory state.
Chronic disruption of metabolic homeostasis, such as occurs in overnutrition
could lead to irregular immune responses.47 In the presence of a continuous nutritional
oversupply, excessive lipid accumulation in adipose tissues results in obesity.48 Since the
bulk of accumulated lipid is stored in adipocytes, the excess nutrition overload causes
adipocytes to rapidly proliferate and expand resulting in cellular stress.47-48 With excess
adiposity, monocytes and macrophages are chronically recruited to adipose tissue which
enhance the secretory capacity of adipose tissue and results in overproduction of proinflammatory TNF-α, IL-6 and leptin and decreased production of anti-inflammatory,
adiponectin.39,49 Consistent with the evidence of a link between the adipose tissue and
inflammation, studies have shown serum levels of adiponectin to inversely correlate with
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fatness, whereas the levels of TNF-α, IL-6, CRP and leptin increase with increasing
adiposity.34,50 Thus, it is firmly established that obese individuals display a characteristic
imbalance of their adipocytokine profile.50 The role of adipocytokines as modulators of
whole body energy balance and inflammatory processes has been demonstrated in most
clinical studies.51 Weight loss due to long-term caloric restriction was associated with
reduced levels of pro-inflammatory adipocytokines and increased levels of antiinflammatory adipocytokines.51 However, some studies have also demonstrated that
dysregulation of these adipocytokines may be observed under conditions associated with
a lack of adipose tissue.52 This is with reference to individuals who though are lean,
usually have increased levels of pro-inflammatory adipocytokines and develop MetS and
T2D. It has been well-established that metabolic changes related to obesity are
principally attributable to abdominal or visceral fat mass rather than subcutaneous fat
mass.53 These fat masses vary by cell size, metabolic activity and potential role in
inflammatory processes.54 Visceral fat, usually measured by waist circumference (WC) is
more pathogenic.53-54 Thus, supposedly, lean individuals may have abnormal distribution
of body fat with more stores in the visceral area.
Adipose tissue function in inflammatory processes and the development of
metabolic disorders in both human and animal systems is unprecedented and continues to
expand. The works of Bazaoglu et al.55 and Yang et al.56 have led to the discovery of the
novel adipocytokines chemerin and omentin. Chemerin is a recently discovered
adipocytokine that is highly expressed in white adipose tissue and liver.55 It is a ligand
activator for G-protein coupled receptor, chemokine-like receptor 1 (CMKLR1) and
thought to modulate innate and adaptive immunity by binding to this receptor found on
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immune cells.57-59 Importantly, chemerin has been shown to have effects on adipose
tissue development, metabolism and inflammation in both human and animal
adipocytes.60 Chemerin mediates inflammatory processes as it is a chemokine to promote
the migration of macrophages and immature dendritic cells and adhesion of macrophages
to the endothelium.57-61
Yang et al.56 described omentin as a novel adipocytokine with insulin-sensitizing
effects. Omentin is a soluble galactofuranose-binding lectin preferentially expressed by
visceral omental adipose tissue but not by subcutaneous adipose tissue.56,62 Omentin is
recognized as an anti-inflammatory adipocytokine that has similar functions as
adiponectin, and thus reduced in disorders involving inflammatory processes.63-66
Moreover, omentin attenuated CRP and TNF-α induced nuclear factor kappa-B (NF-kB)
activation in human endothelial cells.65 Because of the key role that adipocytokines play
in the regulation of glucose and lipid metabolism, they have been suggested to provide
the link between obesity, inflammation and impaired insulin signaling which lead to the
development of obesity-related disorders including MetS and T2D. The association of
chronic low-grade inflammation with insulin resistance is a growing area of research
interest.

Adipocytokines, Insulin Signaling and Insulin Resistance
Insulin is a hormone secreted from the cells localized to the pancreatic β islets and
is necessary for the regulation of metabolic processes and maintenance of normal glucose
levels.67 Thus, insulin secretion is enhanced in response to increased glucose levels, fatty
acids and amino acids. In addition, insulin stimulates glucose uptake in the muscle and
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adipose tissue. Insulin also increases fatty acid synthesis in hepatocytes and adipocytes
and reduces adipocyte free fatty acid production.67 Usually, insulin signaling involves the
binding of insulin to its receptor, composed of two substrates (insulin receptor substrates
1 and 2 (IRS1/2) with two α and two β subunits).68 The binding activates tyrosine kinase
activity which results in autophosphorylation of the receptors on specific tyrosine
residues and formation of binding sites for the recruitment of IRS1/2. Subsequent
phosphorylation of IRS1/2 by the insulin receptor stimulate the phosphatidylinositol 3kinase (PI3K)-AKT/protein kinase B (PKB) pathway which regulates metabolic
functions of insulin including glucose homeostasis and fat regulation.68 Many cell lines
have shown that the PI3K-AKT/protein kinase B (PKB) activation is essential for the
translocation of the glucose transporter 4 (GLUT 4) to the plasma membrane for glucose
uptake in skeletal muscle and adipose tissue.69 Thus, a disturbance of insulin-mediated
signaling pathway may result in systemic hyperglycemia which is known as insulin
resistance.
An imbalance between circulating pro- and anti-inflammatory adipocytokines
may promote insulin resistance in the liver and muscle. Adipocytokines circulate as
signaling molecules to communicate not only with adipose tissue itself but also other
organs such as liver and muscle.36-38 Their interaction with these other insulin sensitive
organs, in particular the liver have been shown to activate key inflammatory signaling
pathways such as the cJun N-terminal kinase (JNK) and inhibitor of nuclear factor kappaB kinase subunit beta/nuclear factor κB (IKKβ/NF-κB).70-71 IKKβ/NF-κB pathways
promote the expression of numerous genes involved in inflammatory processes which
contribute to impaired insulin signaling and induce insulin insensitivity, insulin resistance
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and increased insulin levels.33,70-72 In addition, serine/threonine (Ser) residues on IRS1/2
may be phosphorylated instead of tyrosine residues to suppress downstream processes of
insulin signaling leading to insulin resistance. JNK is a stress kinase that has been shown
to phosphorylate IRS on Ser-307 residues to promote insulin resistance.70 Because the
effects of insulin are blunted in insulin resistance as a result of ineffectiveness of insulin
receptors, pancreatic β cells are persistently stimulated to produce and secrete insulin, and
this eventually results in the development of T2D.
Persistent increased fat deposition off-sets a vicious cycle, where the
adipocyte/macrophage system activates JNK and IKKβ/NF-κB pathways which leads to
increased secretion of pro-inflammatory adipocytokines and these in turn act directly on
both adipocyte/macrophage system and JNK and IKKβ/NF-κB pathways.33 Adiponectin
on the other hand exhibits its anti-diabetic beneficial properties in insulin sensitivity
through activation of AMP-dependent protein kinase (AMPK) to enhance glucose
uptake.73 Adiponectin also inhibits production of pro-inflammatory adipocytokines in
macrophages through suppression of NF-κB activation.74 Besides acting in concert to
activate the cJun N-terminal kinase (JNK) and inhibitor of nuclear factor κB kinase
β/nuclear factor κB (IKKβ/NF-κB) inflammatory pathways, pro- and anti-inflammatory
adipocytokines may act individually through other pathways to affect insulin resistance.
IL-6 and CRP on Insulin Action:
IL-6 is a pleiotropic adipocytokine that is reported to regulate the activities of
several tissues and cells including proliferation of hematopoietic cells, induction of acute
phase response in the liver and inflammation in tissue injury.75 IL-6 is considered to
possess both pro- and anti-inflammatory properties.76 Research has associated IL-6 to the
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modulation of glucose and lipid metabolism through pathways connected to insulin
action.77-78 IL-6 inhibits insulin receptor signal transduction in hepatic cells by enhancing
the expression of the suppression of cytokine signaling-3 (SOCS-3) pathway to induce
insulin resistance.79 However, in a study using animal models, mice that had developed
hepatic inflammation due to IL-6 deficiency showed improvement in insulin sensitivity
upon administration of IL-6.80 Moreover, the role of IL-6 in insulin resistance in other
tissues such as skeletal muscle and adipose tissue is inconsistent.81 In humans, the
administration of IL-6 to healthy individuals increased fasting blood glucose levels,
potentially by inducing insulin resistance.82 While IL-6 has been generally considered to
play a role in insulin resistance, some investigators have suggested that IL-6 prevents
insulin resistance.83 The discrepancies in reports linking IL-6 to insulin resistance has
been attributed to the likely dependence on the site, level and duration of IL-6 expression
and its anti-inflammatory properties.76,80-81 C-reactive protein is induced by IL-6 and is
synthesized by the liver.20 CRP acts as part of the innate immune system and induces
phagocytosis of macrophages. In acute inflammation, CRP marks damaged cells to make
them easier to be recognized by macrophages.84 Several studies have associated insulin
resistance with increased CRP levels depicting its role in chronic low-grade inflammation
and metabolic disease processes.85-87 The mechanism through which CRP may induce
insulin resistance is unclear. However, it is possible that CRP propagates the
inflammatory and insulin resistance effects of IL-6.
Leptin on Insulin Action:
Leptin is the first adipocytokine to be isolated from the adipose tissue.88 Leptin is
a product of the human obese (ob) gene located on chromosome 7.89 Human leptin is a
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16kDa protein of 167 amino acids. It is released into circulatory from the adipose tissue
and acts in the hypothalamus to control hunger and energy expenditure and thus regulates
body weight.90 Thus, leptin deficient mice display marked obesity and insulin
resistance.88 Until decades ago, leptin had been considered to only play a role in
regulation of energy balance. More recent data shows that leptin is a pro-inflammatory
adipocytokine and also seems to play a role in inflammatory response. Leptin has
structural properties similar to IL-6 and is indicated to also induce insulin resistance
through the SOCS-3 pathway.91 In addition, leptin interacts with the immune system to
enhance the release of pro-inflammatory IL-6 and TNF-α by macrophages.92-93 This
integrated system of pro-inflammatory adipocytokines augments the resistant effect of
leptin on insulin action. It is also suggested that leptin may directly regulate the secretion
of insulin by pancreatic β cells.94 Leptin levels increase with increasing BMI due to leptin
resistance and this is attributable to impaired leptin transport in blood brain barrier which
is induced by SOCS-3.91
Chemerin and Omentin on Insulin Action:
In vivo and in vitro studies have demonstrated that chemerin may influence
glucose homeostasis through reduction of insulin sensitivity.95-96 The effect of chemerin
on insulin action is suggested to be elicited through alteration of GLUT2 expression
and/or activity.97-98 GLUT2 promotes insulin secretion in pancreatic β cells by increasing
the intracellular levels of glucose.98 Evidence supporting the reduction of glucoseinduced insulin secretion was demonstrated in chemerin deficient mice. Chemerin and its
receptor signaling positively modulated the expression of the pancreatic β-cell-specific
transcriptional factor, MafA, expressed in pancreatic β cells that positively influence
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GLUT2 activity.98 Thus, reduction of MafA and subsequently GLUT2 expression may be
the explanation for the reduced insulin release. Omentin is an anti-inflammatory
adipocytokine that is inversely associated with obesity and insulin resistance.63 Omentin
has therefore been shown to enhance insulin sensitivity by increasing the Akt/PkB
phosphorylation and promoting insulin-facilitated glucose uptake in human omental and
subcutaneous adipocytes.65 The mechanism by which omentin achieves the positive
effect on insulin action remains to be clarified.
The role of insulin resistance in mediating adiposity induced-inflammation and
the development of MetS and T2D is recognized as an interplay between the metabolic
and immune pathways.34 Insulin has pleitropic functions and as such, insulin resistance
and insulin deficiency result in hyperglycemia. The hyperglycemia state is closely linked
with other metabolic derangement such as hypertension and hyperlipidemia due to further
activation of inflammatory pathways.99 Taken together, the balance of animal and human
studies support a role for all these adipocytokines as regulators of insulin resistance, the
core defect that underlies the development of MetS and T2D.
Roles of Adipocytokines in Metabolic Syndrome and Type 2 Diabetes
Various cross-sectional studies, longitudinal studies and randomized control trials
conducted to investigate the association between obesity and the effects of
adipocytokines in the development of insulin resistance and subsequently MetS and T2D
have shown conflicting results. While some studies demonstrated positive associations,
others found no significant associations.
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IL-6 and CRP with MetS and T2D:
Abbatecola et al.100 used a cross-sectional study design to evaluate the association
between pro-inflammatory adipocytokines, insulin resistance and components of the
MetS, which the researchers termed as insulin resistance syndrome. Insulin resistance
was calculated with the homeostatic model assessment (HOMA-IR). This large
population-based study conducted in 1146 older persons without T2D, showed a positive
correlation between plasma levels of TNF-α, IL-6, CRP, interleukin-1 receptor antagonist
(IL-1ra) and soluble IL-6 receptor (sIL-6R) and insulin resistance. Moreover, as the
degree of insulin resistance increased, the levels of TNF-α, IL-6, CRP, and IL-1ra also
increased. In addition, body mass index (BMI), a measure of obesity, triglycerides (TG)
and IL-6 were associated with higher insulin resistance.
A study that measured the levels of TNF-α, IL-6, and CRP, and their soluble
receptors, in obese postmenopausal women with and without MetS showed significantly
higher levels of soluble TNF-α receptor 1 (sTNFR1) in those with MetS. The number of
MetS components significantly correlated with plasma concentrations of sTNFR1, but
was not related to plasma TNFα, sTNFR1, IL-6, IL-6sR, or CRP. The authors concluded
that the severity of the MetS is associated with body composition, visceral adiposity, and
inflammation.101
The Women’s Health Initiative study prospectively investigated the relationships
of plasma levels of tumor necrosis factor α receptor 2 (TNF-α-R2), IL-6, and CRP with
the incidence of T2D. The study included non-Hispanic white, Hispanic, non-Hispanic
Black and Asian/Pacific Islander women aged 50 to 79 years. After a follow-up period of
5.9 years, 1584 women who developed T2D were matched with 2198 women who did
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not have T2D. The results of the study showed that all three pro-inflammatory
adipocytokines were significantly associated with increased T2D risk, however CRP had
the highest estimated relative risk. Moreover, mutual adjustment for each adipocytokine
did not attenuate the consistent and significant associations of IL-6 and CRP with
increased risk of T2D in all ethnic groups. Subgroup analysis indicated more evident
interactions of TNF-α-R2, IL-6, and CRP with T2D risk in women with BMI ≥25
kg/m2.12
Han et al.102 have also considered the role of CRP in the development of both
MetS and T2D in the same study. The researchers studied 515 men and 729 women who
were free of diabetes at baseline, but had one or none of other metabolic condition
including hypertension and dyslipidemia. Serum levels of CRP, indices of adiposity,
insulin resistance, plasma glucose concentrations, lipid profile and blood pressure were
measured at baseline and at the end of the study (6 years). CRP correlated significantly
with components of the MetS in both men and women. Men had a lower risk to develop
MetS compared to women and this corresponded with lower BMI, waist circumference,
lower concentrations of CRP, HOMA-IR, high density lipoprotein cholesterol (HDL-C),
TG, lower levels of systolic blood pressure (SBP) and diastolic blood pressure (DBP) in
men. Subjects with the highest risk to develop MetS and T2D also had the highest levels
of CRP at baseline. A comparison of the clinical value of CRP with adiposity and insulin
resistance measures as a risk factor for the development of MetS showed that the
combined effects of CRP, BMI and HOMA-IR had greater predictive power than the
individual markers.
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Leptin with MetS and T2D:
There is abundant data indicating that leptin can impact insulin sensitivity and that
hyperleptinaemia may underlie insulin response. Some evidence also exist which provide
further insight into possible association between leptin and MetS and T2D. Zimmet et
al.103 in a population-based study of Western Samoans with and without T2D, determined
the relationship of serum leptin with insulin sensitivity measured by HOMA and
components of the MetS. While the results indicated higher leptin levels in men with than
without T2D, adjustment of BMI made the difference no longer significant. Leptin levels
did not differ between women with and without T2D. Leptin was significantly, positively
correlated with BMI, insulin levels, and SBP and DBP when age and gender were taken
into consideration, irrespective of diabetes status. Moreover, in regression models, leptin
was associated with insulin sensitivity independent of age, BMI, waist/hip ratio, TG,
HDL-C, SBP and DBP levels. Furthermore, evidence supporting the relationship of leptin
with insulin action in T2D was demonstrated by Ozata et al.104 who found that
improvement in glycemic control following a 4 month treatment with sulfonylurea in a
group of poorly controlled obese women with T2D matched with those without T2D was
associated with reduced serum leptin levels. However, this was not associated with
correction of lipid abnormalities.
In Mexican Americans, the serum leptin levels were analyzed in relation to
obesity and T2D. The results of the study indicated that leptin resistance is prevalent in
this Hispanic ethnic minority subgroup. In addition, higher leptin levels were associated
with obesity irrespective of diabetes status.105 In 144 Saudi Arabian men, higher leptin
levels were associated with T2D and coronary heart disease risk factors. Moreover, leptin
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levels were positively associated with TG and SBP when individuals were obese and had
insulin resistance and findings were also associated with MetS.106 Conversely,
Abdelgadir and colleagues.107 found that higher levels of leptin were not associated with
T2D in 104 indigenous Africans from Sudan with T2D. Despite the finding of no
association, serum leptin levels positively correlated with HOMA of both beta-cell
function and insulin resistance in individuals with T2D and only insulin resistance in
those without T2D.
Chemerin and Omentin with MetS and T2D:
There is limited research on the relationship of chemerin and omentin with MetS
and T2D, but available data have shown positive associations.
Bozaoglu et al.55 found that in an animal model of obesity and T2D, gene
expression of chemerin was significantly higher in the adipose tissue of obese and T2D
models than lean and normoglycemic models. When the investigators measured serum
levels of chemerin in human samples, there was no significant difference between those
with compared to without T2D. However, chemerin levels were significantly associated
with BMI, TG and blood pressure measures in individuals without T2D. In a cohort of 55
healthy non-obese Caucasians and 181 at risk for the MetS, chemerin was evaluated as a
marker of MetS and its predictive accuracy was determined. Chemerin levels were higher
in individuals with the MetS than in healthy controls. Moreover, serum chemerin levels
positively correlated with age, serum glucose, HDL-C, TG, blood pressure and the
number of metabolic risk factors. With a cut-off value of 240µg/L, chemerin predicted
presence of MetS with a 75% sensitivity and 67% specificity.108
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Available data have shown that circulating levels of omentin are significantly
decreased in obese individuals and those with T2D.109 Additionally, circulating omentin
levels are reduced in association with BMI, leptin, waist circumference (WC), HOMA-IR
and increased with adiponectin and HDL-C.110 Clinical studies have also revealed a
positive association between omentin levels and vascular health, suggesting an important
role for omentin in cardiovascular diseases.63,66
Pan et al.64 utilized a cohort with impaired glucose tolerance, newly diagnosed
and untreated T2D individuals and healthy controls. Serum omentin levels were assayed
and their relationship with BMI, glycated hemoglobin (A1C), plasma glucose, fasting
insulin, HOMA-IR, TNF-α and IL-6 levels were determined. The results indicated that
serum omentin levels were lower in those with glucose tolerance and T2D than in the
control group. There was a negative correlation between omentin levels and BMI,
HOMA-IR, plasma glucose, fasting insulin, TNF-α and IL-6. Further, HOMA-IR and
BMI were the independent predictors of serum omentin levels. A similar research
undertaken by Shibata and colleagues111 using Japanese men without diabetes further
demonstrated the role of omentin in MetS. The authors investigated the association of
omentin with the metabolic risk factors. In this study, subjects were categorized
according to omentin levels as group 1 (those having <2.59 ng/ml); group 2 (those having
≥2.59 ng/ml); group 3 (those having ≥2.66 ng/ml) and group 4 (those having ≥2.72
ng/ml). The results of the investigation showed an inverse correlation between omentin
levels and the number of metabolic risk factors including WC, dyslipidemia, high blood
pressure and glucose intolerance.
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Existing studies that examined ethnic differences in established adipocytokines
such as TNF-α, IL-6 and CRP have focused on general ethnic categories and not
individual subgroups of ethnicities.12,112-114 Haitian and African Americans are two
distinct ethnic minority subgroups but are commonly classified as non-Hispanic Blacks.
As a result, it is unclear whether adipocytokines may differ between Haitian and African
Americans and whether this difference may distinguish risk for T2D and related health
outcomes between the two ethnic subgroups. Despite having a better diet quality, Haitian
Americans have the worse glycemic control compared to African Americans.115-116 Such
an important difference supports the need to treat each ethnicity as distinct in diabetes
studies and specifically target ethnic minority subgroups in order to identify and reduce
disease risks typical for each ethnicity.
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Specific Aims and Hypotheses
Specific Aim 1: To evaluate the relationships between metabolic syndrome and
inflammation, as measured by serum levels of IL-6 and CRP in Haitian and African
Americans with and without T2D.
Hypothesis 1:
a. Metabolic syndrome will be positively associated with IL-6 and CRP levels,
independent of diabetes status and ethnicity.
b. Haitian Americans with T2D will have increased levels of IL-6 and CRP,
compared to African Americans with T2D.
Rationale: Adipocytokines play important roles in nutrient metabolism and the
subsequent development of metabolic syndrome. This aim will provide information on
differences in these adipocytokines between Haitian and African Americans and
participants with and without T2D and their association with metabolic syndrome.
Specific Aim 2: To investigate the relationships of two novel adipocytokines: chemerin
and omentin; diabetes status; and two non-Hispanic Black ethnicities: Haitian and
African Americans.
Hypothesis 2:
a. Type 2 diabetes (T2D) will be positively associated with chemerin levels and
negatively associated with omentin levels, independent of ethnicity.
b. Haitian Americans with T2D will have increased chemerin levels and reduced
omentin levels, compared to African Americans with T2D.
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Rationale: T2D is considered a state of chronic low-grade inflammation. Haitian
Americans have been found to have worse glycemic control and T2D outcomes compared
to African Americans. This aim will therefore enable us understand these novel
adipocytokines and the differences in these markers not only between participants with
and without diabetes but between the two ethnicities and further explain those factors
which are independently linked with inflammation in this population.
Specific Aim 3: To assess the relationships between BMI, insulin resistance, as measured
by homeostatic model of assessment-insulin resistance (HOMA-IR) values and leptin in
Haitian and African Americans with and without T2D.
Hypothesis 3:
a. BMI and insulin resistance are positively associated with leptin levels,
independent of diabetes status and ethnicity.
b. Haitian Americans with T2D will have increased levels of leptin, compared to
African Americans with T2D.
Rationale: Leptin, a pro-inflammatory adipocytokine is increased in obesity and is linked
to insulin resistance and T2D. This aim will enable us to understand the relationships
between leptin, obesity and insulin resistance and how they differ by ethnicity and
diabetes status.
Research presented here analyzed secondary data from the parent study conducted
by Huffman et al. (2009) which was to compare cardiovascular risk factors of ethnic
minorities with and without T2D. In addition, existing serum of participants from the
parent study stored at -700C was used to obtain data on the serum levels of
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adipocytokines. While serum levels of IL-6, leptin, chemerin and omentin were measured
in the Human Nutrition Laboratory at Florida International University, CRP levels were
obtained from the parent study. TNF-α which was initially proposed to be part of this
research was not included in the analyses due to its extremely low detectability in more
than 50% of the samples assayed. For the purposes of this dissertation, discussions will
be restricted to IL-6, CRP, leptin, chemerin and omentin. The results of the research will
be discussed as three separate manuscripts which will focus on the specific aims and
hypotheses described.
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CHAPTER III: INFLAMMATORY ADIPOCYTOKINES AND METABOLIC
SYNDROME IN HAITIAN AND AFRICAN AMERICANS WITH AND WITHOUT
TYPE 2 DIABETES
ABSTRACT
Background: Obesity and metabolic syndrome (MetS) often occur jointly and have been
associated with type 2 diabetes and cardiovascular diseases. These metabolic processes
may partially be explained by a pro-inflammatory state. Ethnic subgroups within the nonHispanic Black population have not been characterized in metabolic disorder studies. The
purpose of this study was to assess levels of IL-6 and CRP by ethnicity and diabetes
status; and determine whether MetS will be associated with higher levels of IL-6 or CRP.
Methods: Cross-sectional data from 471 participants (230 Haitian Americans and 241
African Americans; 240 with and 231 without T2D) recruited from various community
sources in South Florida, were included in this study. Results: African Americans had
higher log IL-6 and log CRP levels than Haitian Americans (P<0.001). Haitian
Americans with and without MetS had lower log IL-6 levels and log CRP than African
Americans with and without MetS, respectively (P < 0.001). Log IL-6 and log CRP
correlated with higher waist circumference in all groups except for log IL-6 in African
Americans without T2D. Log IL-6 and log CRP positively correlated with triglycerides in
Haitian Americans with T2D. Log IL-6 was negatively correlated with HDL-C in Haitian
Americans with T2D. Higher levels of log CRP (β = 0.34, SE = 0.14, P = 0.012), but not
log IL-6 (P = 0.727) were associated with MetS. Conclusion: Ethnic-centered health
interventions that focus on improving these metabolic parameters may be the key to
reducing the risk for T2D and cardiovascular diseases in this population.
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INTRODUCTION
Metabolic syndrome (MetS), the clustering of complex abnormalities, includes a
large waist circumference, dyslipidemia, hypertension, and impaired glucose tolerance.
These components of MetS, are a multiplex risk factor for type 2 diabetes (T2D) and
cardiovascular diseases (CVD).1-3 Population based estimates from the National Health
and Nutrition Examination Survey (NHANES) 1999-2006 show that approximately 1 out
of every 3 adults ≥ 20 years has MetS.4 Given the dramatic trend in the increasing
prevalence of obesity, it is projected that the prevalence of MetS will nearly double in the
next 15 years.4 The association of MetS with obesity is largely due to chronic low-grade
inflammation found in both states.5-9 Obesity is associated with dysfunctional adipose
tissue which leads to altered physiological balance of adipocytokines and is associated
with hyperinsulinemia, insulin resistance, and a pro-inflammatory state. The recognition
of the key role of chronic low-grade inflammation in the clinical expression of MetS has
developed in the past decade.9 Interleukin-6 (IL-6), an important pro-inflammatory
adipocytokine released by adipocytes has been found to integrate key metabolic pathways
including insulin signaling, glucose and lipid metabolism.10 IL-6 regulates hepatic acutephase response and stimulates the production of C-reactive protein (CRP) by the liver.11
Recent in vitro studies have demonstrated the extrahepatic production of CRP by human
adipocytes,12 which elicits the likelihood that CRP may basically be a marker of obesity
in individuals who later develop MetS and T2D. Several studies have demonstrated an
increase in circulating levels of IL-6 and CRP in subjects with MetS.13-16 The graded
positive relationships between IL-6 and CRP, and components of the MetS, particularly
waist circumference, a measure of obesity, and hyperinsulinemia have also been
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reported.13,16 Similarly, high serum IL-6 and CRP have shown significant associations
with MetS in individuals with and without T2D in diverse racial and ethnic
populations.13,17-18
Metabolic syndrome and levels of IL-6 and CRP vary widely across selfdescribed race/ethnic groups in the United States.4,19 Studies have consistently shown that
African Americans as compared to Mexican Americans and Whites are less likely to be
classified as having MetS due to lower prevalence of dyslipidemia.20-22 Yet, African
Americans exhibit somewhat increased hyperinsulinemia, hypertension, and higher
prevalence and risk of T2D and cardiovascular diseases.4,23 Moreover, African Americans
as compared to Whites have higher levels of IL-6 and CRP.24-25 Whereas a sizeable
number of studies have described the associations between MetS, inflammation and long
term metabolic disease risks in African Americans, these associations among Haitian
Americans are lacking, despite their high susceptibility to develop T2D with poor
outcomes.26 African Americans as compared to Haitian Americans are found to be more
obese and have increased hyperinsulinemia, two major underlying defects associated with
MetS.27 Considering the fact that these two components of MetS are also strong
determinants of IL-6 and CRP levels, the observed differences may have the potential to
confer variability in the levels of IL-6 and CRP and their association with MetS among
the two ethnic subgroups. Therefore, this study aimed to analyze Haitian and African
Americans with and without type 2 diabetes to 1) determine the differences in levels of
IL-6 and CRP by ethnicity, diabetes and MetS statuses; 2) assess whether MetS will be
associated with higher levels of IL-6 and CRP.
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METHODS
Research design and Participants
This was a cross-sectional study conducted to study cardiovascular risk factors in
Haitian and African Americans with and without T2D. Study participants were recruited
from Miami- Dade and Broward Counties, Florida. African American participants with
and without T2D were randomly selected from lists of addresses obtained from the
Knowledge Base Marketing, Inc., Richardson, TX, USA. About 7550 letters were mailed
to African Americans to request their participation. Of the letters mailed, 4% (n = 256)
responded. As a result of unavailability of a similar database of mailing addresses for
Haitian Americans, community based sources were used to recruit Haitian Americans (n
= 259). Recruitment print advertisements were posted in local Haitian supermarkets,
churches, and restaurants; and flyers were also distributed to Florida International
University (FIU) faculty, staff and students. In addition, local diabetes educators and
community health professionals were requested to assist in recruitment efforts and
announcements were also aired on a Creole radio station. Interested individuals were
interviewed on phone and were fully informed of the study purpose. For all those
interviewed, age, gender and self-identified ethnicity (African American and Haitian
American) were confirmed. Self-reported T2D status was confirmed based on fasting
plasma glucose (FPG) and glycosylated hemoglobin (A1C), diabetes duration and use of
diabetes medications. Eligibility also included age ≥35 years and absence of chronic
conditions such as kidney failure, hepatitis, HIV and cancer. Eligible respondents were
requested to participate in the study at the Human Nutrition Laboratory at FIU.
Participants were directed to be in a fasting state, and refrain from smoking and
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exercising 8 hours prior to their visit. This study was approved by the Institutional
Review Board at FIU. Signed informed consent in English or Creole was obtained from
participants on their initial appointments to the laboratory. Twelve participants (Haitian
Americans = 8; African Americans = 4) were reclassified as having diabetes according to
the criteria specified by the American Diabetes Association and referred to their
physicians. Participants with missing values (n = 34) and outliers (n = 4) for IL-6 were
excluded. The final data analysis was confined to 230 Haitian Americans and 241 African
Americans with complete data on IL-6, CRP and MetS.
Measurement of Study Variables
a. Socio-demographic
A validated socio-demographic questionnaire was used to collect information on age,
gender, smoking status, and use of lipid, nonsteroidal anti-inflammatory drugs (NSAIDs)
and oral hypoglycemic medications.
b. Anthropometric measurement
Height and weight were measured to the nearest 0.5 cm and 0.1 kg respectively, using a
SECA balance scale (Seca Corp, Columbia, MD). BMI was calculated as weight in
kg/height in m2. Waist circumference was measured with a non-stretchable measuring
tape, midway between the lower rib margin and the iliac crest and was reported to the
nearest 0.1 cm. Blood pressure was measured twice and averaged with the participants in
a sitting position at rest for fifteen minutes with a sphygmomanometer.
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c. Blood sampling and biochemical analysis
Venous blood samples were collected from each participant after an overnight fast of at
least 8 hours. A trained and certified phlebotomist was in charge of blood draw and this
ensured minimal risk to the participants. Blood samples were collected in a Vaccutainer
Serum Separator tube, then coagulated for 30-45 minutes and centrifuged at 2500 RPM
for half an hour to obtain serum. The serum was aliquoted into 3 labeled plastic tubes for
1) glucose determination 2) lipid panel analysis and 3) stored at -700C for subsequent
analyses. Glucose levels were determined by hexokinase enzymatic methods, and lipid
panel was assayed using enzymatic methods (Laboratory Corporation of America, FL,
USA). Glycated hemoglobin (A1C) was measured in whole blood samples via Roche
Tina Quant method (Laboratory Corporation of America, FL, USA). Serum fasting
insulin levels were determined using a commercially available enzyme-linked
immunosorbent assay (ELISA, Millipore, St Charles, MS, USA). Serum C-reactive
protein (CRP) was analyzed with the Immulite method (Vascular Disease Intervention
and Research Laboratory, OK, USA). Interleukin 6 (IL-6) was measured in serum at the
Human Nutrition Laboratory at FIU with the ELISA method (BD Biosciences, San Jose,
CA, USA). Briefly, 50µl of ELISA Diluent was pipetted into each well followed by the
addition of 100µl of standards, blank and samples. After 2 hours of incubation at room
temperature followed by washing, 100µl of Working Detector was added and incubated
for an hour. After a second washing step, 100 µl TMB One-Step Substrate Reagent was
added and incubated for half an hour. The reaction process was stopped by addition of 50
µl of Stop Solution. The absorbance of the resulting product was measured at 450nm with
a spectrophotometer. A microplate reader capable of creating a standard curve plotted the
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mean absorbance values against the IL-6 concentrations of standards. The software used
the standard curve to determine the concentrations of the unknown samples. The
sensitivity of the ELISA assay was 2.2 pg/ml and the range was 2.2–300 pg/ml. The
intraassay and interassay coefficients of variation were both less than 10%.
d. Metabolic syndrome (MetS) definition
The National Cholesterol Education Program Adult Panel III (NCEP-ATP III) criteria for
MetS1 was used to classify participants as having MetS if they met three or more of the
following: 1) waist circumference (WC) > 102 cm for men and > 88 cm for women; 2)
fasting plasma glucose (FPG) ≥ 110 mg/dL; 3) triglyceride (TG) ≥ 150 mg/dL; 4) highdensity lipoprotein cholesterol (HDL-C) < 40 mg/dL for men and < 50 mg/dL for
women; or 5) systolic blood pressure ≥ 130 mmHg and/or diastolic blood pressure ≥ 85
mmHg.
Data Analysis
The IBM Statistical Package for the Social Sciences (SPSS) version 21 (IBM
Corporation, Chicago, IL, USA) was used for statistical analyses. Because the
distributions of insulin, IL-6 and CRP values were skewed, these variables were logtransformed to approach normality. Descriptive statistics using independent samples t-test
and analysis of variance (ANOVA) followed by Tukey post hoc tests, for continuous
variables and χ2 tests for categorical variables were used to assess the differences in
means stratified by ethnicity, diabetes status and MetS to test the first aim. To evaluate
the second aim, partial correlations adjusted for age, gender and BMI, and hierarchical
multiple linear regressions were conducted. The log transformed serum concentrations of
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IL-6 and CRP served as dependent variables in separate linear regression equations, and
MetS (yes/no), ethnicity (Haitian Americans/African Americans) and diabetes status
(yes/no) as independent variables. Regression models were adjusted for age, gender
(male/female), BMI, smoking (yes/no), NSAIDs (yes/no), lipid and oral hypoglycemic
medications (yes/no). The results were considered statistically significant at P-value
<0.05.
RESULTS
The demographic and clinical characteristics of the participants are shown as
comparison of means stratified by ethnicity and diabetes status (Table 1). Overall, both
Haitian and African Americans had similar prevalence of the MetS and T2D. Haitian
Americans as compared to African Americans were significantly older (56.3±10.5) and
had higher A1C and SBP. African Americans had significantly higher mean serum log
IL-6 (2.14±.5 vs 1.69±.7) and log CRP levels (1.23±1.2 vs 0.50±1.1) than did Haitian
Americans, respectively (P < 0.001). Compared with Haitian Americans, African
Americans had higher mean BMI (P< 0.001), WC (P< 0.001), and were more obese (P<
0.001). African Americans also had higher TG levels (P< 0.001) and log insulin levels
(P< 0.001), and lower HDL-C (P = 0.017). Current smoking was proportionally higher
among African Americans (38.2%) than among Haitian Americans (6.5%). African
Americans were more likely than Haitian Americans to use NSAIDs (39.4% vs 27.4%),
whereas the use of lipid medications and oral hypoglycemic medications was not
significantly different between the two ethnic subgroups. The mean age of participants
with T2D (n = 240) was 55.9±10.2; where the majority were not current smokers (78.7%)
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and used medications (lipid medications {41.3%}, NSAIDs {42.5%} and oral
hypoglycemic medications {82.5%}). A significant difference was observed (P<0.05)
between mean BMI, WC, and percentage obesity of participants with and without T2D.
Participants with T2D as expected had significantly higher levels of A1C (P< 0.001),
FPG (P<0.001), SBP (P = 0.024), serum log IL-6 (P = 0.028) and higher percentage of
MetS (89.6%). The mean log CRP levels (P = 0.239) did not differ significantly between
participants with and without T2D. Moreover, no significant difference in the levels of
TG, HDL-C, DBP and log insulin was observed between participants with and without
T2D.
Figures 1 & 2 further show the differences in levels of mean log IL-6 and log
CRP with MetS by ethnicity using ANOVA followed by Tukey post hoc test. Haitian
Americans with and without MetS had lower mean log IL-6 levels than African
Americans with and without MetS (1.7±.6 and 1.6±.7 vs. 2.1±.5 and 2.1±.4, respectively;
P< 0.001). Nevertheless, the mean log IL-6 levels of Haitian Americans with MetS were
not significantly different from those of Haitian Americans without MetS (1.7±.6 vs.
1.6±.7; P= 0.123). This observation was also present among African Americans with and
without MetS (2.1±.5 vs. 2.1±.4; P= 1.000) (Fig. 1). Figure 2 shows that the mean log
levels of CRP in Haitian Americans with MetS were lower than in African Americans
with MetS (0.6±1.0 vs. 1.4±1.1; P< 0.001), but not significantly different compared to
African Americans without MetS (0.6±1.0 vs. 0.7±1.3; P= 0.970). Haitian Americans
without MetS had lower mean CRP levels compared to Haitian Americans with MetS
(0.2±1.1 vs. 0.6±1.0; P= 0.017), and African American with and without MetS (0.2±1.1
vs. 1.4±1.1 and 0.7±1.3; P< 0.001 and P= 0.024, respectively). African Americans with
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MetS had higher mean log CRP levels compared to African Americans without MetS
(1.4±1.1 vs. 0.7±1.3; P< 0.001).
Partial correlations between levels of log IL-6 and log CRP with MetS and each
component of MetS by ethnicity and diabetes status controlled for age, gender and BMI
are shown in Table 2. The levels of log IL-6 did not correlate with MetS in neither
Haitian nor African Americans with and without T2D, whereas log CRP showed a
positive correlation with MetS among Haitian Americans with T2D and African
Americans with and without T2D. High levels of log IL-6 and log CRP corresponded
with higher WC in all groups except for log IL-6 in African Americans without T2D.
There was a positive correlation between log IL-6 and log CRP with TG only in Haitian
Americans with T2D (r = 0.35, P< 0.001 and r = 0.18, P= 0.046). In addition, log IL-6
was negatively correlated with HDL-C in only Haitian Americans with T2D (r = -0.18, P
= 0.048). Log insulin levels was positively correlated with log CRP in African Americans
with and without T2D and Haitian Americans without T2D. There was no significant
correlation between log IL-6 and log CRP with FPG, SBP and DBP in either Haitian or
African Americans with and without T2D.
Multiple linear regression models performed to further test the secondary aim that
MetS will be associated with higher levels of log IL-6 and log CRP are illustrated in
Tables 3 and 4. The model was run with the primary variables and covariates: age,
gender, BMI, smoking and intake of NSAIDs, lipid and oral hypoglycemic medications.
After adjustment, the hypothesis was partially explained since log IL-6 was not
significantly associated with MetS (Table 3), but MetS explained only log CRP (Table 4).
Being African American and having a high BMI were positively associated with both log
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IL-6 and log CRP levels. High levels of log CRP levels were also significantly associated
with being female, and higher age had a trend towards significant association with higher
levels of log IL-6 levels. A test of the interaction effect between ethnicity and diabetes
status showed that the interaction term was not significant. There was no relationship
between T2D status, current smokers, intakes of NSAIDs, lipid and oral hypoglycemic
medications with log IL-6 and log CRP.
DISCUSSION
The prevalence of metabolic syndrome (MetS), along with type 2 diabetes (T2D)
and cardiovascular diseases (CVD), has increased steadily in the United States over the
past decade and is considered as a national epidemic.2-4 MetS and obesity often coexist
and corresponds to hyperinsulinemia and insulin resistance with increased levels of proinflammatory adipocytokines in persons with MetS.9 African Americans had higher IL-6
and CRP levels with or without MetS. This may be attributed to the fact that African
Americans were more obese (higher BMI and WC) and had higher insulin levels. In
addition, higher IL-6 and CRP levels were seen among participants with than without
T2D, however, the difference was not significant for CRP. This might be due to only
modest differences in BMI and insulin levels between the two groups. It is worth
mentioning that although Haitian Americans had lower metabolic risk factors, their
prevalence of MetS was similar to that of African Americans. This might be as a result of
the similar prevalence of T2D among the two groups, since individuals with T2D are
more likely to have higher prevalence of MetS,28 which is confirmed in our study.
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Chronic low-grade inflammation, as characterized by increased circulating levels
of pro-inflammatory adipocytokines, is a key feature of chronic diseases including
obesity, MetS, T2D and CVD.29 Several studies have associated circulating levels of proinflammatory adipocytokines such as IL-6 and CRP, with metabolic risk factors such as
obesity and insulin resistance.30 Interleukin 6 is a pleiotropic adipocytokine that plays a
key role in chronic inflammation.10 It is a central regulator of the acute-phase response
and a major determinant of hepatic synthesis of CRP.11 IL-6 is secreted by adipocytes and
macrophages/monocytes recruited into the adipose tissue with increasing adiposity.10
Thus, IL-6 is considered to not only modulate glucose and lipid metabolism, but the
innate immunity. IL-6 has been generally considered to play a role in developing insulin
resistance by inhibiting insulin receptor signaling via expression of suppressor of
cytokine signaling 3 (SOCS3) in hepatocytes31 and may provide the link between
metabolic and immune system pathways in the development of MetS and eventually
T2D. However, some studies have reported that IL-6 is not strongly associated with MetS
as compared to CRP.32-34 C-reactive protein is the chief downstream mediator of the
acute-phase response, and may account for the inflammatory and insulin resistance
effects of IL-6.11,31 Alternatively, reverse causation has been implicated whereby
decreased insulin sensitivity may enhance hepatic CRP production independent of IL-6
levels.35 This is because insulin has anti-inflammatory effect which counteracts the
inflammatory effects of insulin resistance and increased synthesis of hepatic CRP.
Recently CRP has been produced by adipocytes and may be considered as an
adipocytokine.12 Among the inflammatory adipocytokines, CRP has been the main focus
of previous investigations and has been shown to be strongly associated with MetS, T2D
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and CVD independent of traditional risk factors such as BMI and insulin resistance.1213,16,32-34

Moreover compared to other pro-inflammatory adipocytokines, CRP

measurements are more sensitive due to a relatively long half-life and no circadian
variation.
The present study shows a predictable, but partially discordant association
between MetS and increasing levels of IL-6 and CRP. Specifically, CRP showed a
significant positive relationship with MetS, whereas a nonsignificant negative
relationship was observed between MetS and IL-6, after adjusting for BMI and other IL-6
and CRP confounders. Interestingly, other studies have also shown that CRP, but not IL-6
is associated with MetS and that CRP seemed appropriate for detecting MetS among
representative pro-inflammatory markers.32-34 However, the negative relationship in our
study might be due to the influence of lipid lowering medications taken mainly by
individuals with MetS to reduce adiposity.36 IL-6 is a direct product of adiposity, a major
contributor to MetS, thus once adiposity is taken into account, this might have diminished
association between having MetS and IL-6. On the other hand, CRP is a nonspecific proinflammatory marker which may not be directly affected by adiposity.37 In effect, CRP
has been shown to be more strongly associated with MetS than IL-6 independent of
obesity markers and is considered the best standardized pro-inflammatory marker of
metabolic and cardiovascular disorders.38-40 Pro-inflammatory adipocytokines,
particularly CRP has therefore been proposed to be considered a component of the
classification of MetS.41 Moreover, the levels of IL-6 did not correlate with MetS in
neither Haitian nor African Americans with and without T2D, whereas CRP showed a
positive correlation with MetS among Haitian Americans with T2D and African
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Americans with and without T2D. On the other hand, IL-6 correlated with several
components of the MetS: positively with WC except in African Americans with T2D, TG
in Haitian Americans with T2D, and negatively correlated with HDL-C in Haitian
Americans with T2D. This may be in support of the view that chronic inflammation is a
component of the MetS and may act as the initial trigger to the development of MetS.9,41
CRP was also positively correlated with WC in Haitian and African Americans with and
without T2D, TG in Haitian Americans with T2D and log insulin in African Americans
with and without T2D and Haitian Americans without T2D. Both IL-6 and CRP were not
correlated with FPG, SBP and DBP in either Haitian or African Americans with and
without T2D. The lack of correlation of CRP with FPG has been previously reported.32
Because pancreatic β-cells compensate to increase insulin synthesis earlier on in impaired
glucose tolerance, FPG levels may remain within normal limits.
We found ethnically-specific differences in IL-6 and CRP even when adjusting
for BMI. One possible reason for the ethnic differences in the level of IL-6 is due to the
presence of variants of cytokine gene single nucleotide polymorphisms. Delaney et al.42
discovered that allelic variation in the enhancer regions of the cytokine genes may
modify the expression of some cytokines. The G/G genotype which causes high
expression of IL-6 and as a result increases IL-6 production, has been predominantly
found in African Americans, and may explain higher levels of IL-6 among this ethnic
subgroup. Additionally, several studies have reported that the association between CRP
and adiposity does not fully explain the higher CRP levels in populations of African
ancestry.43-44 In a recent large genome-wide association study, Reiner and colleagues45
identified several CRP-associated alleles of triggering receptors expressed by myeloid
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cells 2 (TREM2) in African American women. The authors reported that the strongest of
these alleles which is associated with higher levels of CRP is present only in African
ancestral populations. Therefore, future studies should investigate the activities of these
genes also in Haitian Americans to better distinguish inflammatory processes between the
two non-Hispanic Black subgroups. Other nongenetic factors such as diet quality and
lifestyle factors (including physical activity and smoking) which have been shown to be
better in Haitian Americans than Africans Americans,46 may have accounted for the
lower inflammatory status in Haitian Americans. Although, smoking was not
significantly associated with levels of IL-6 and CRP in regression analysis, African
Americans had a higher percentage of smokers in our study. Smoking has been found to
be a strong risk factor for the chronic low-grade inflammation based on increased
circulating levels of IL-6 and CRP.47-48
The association of inflammatory adipocytokines with diabetes are mixed.49-51 The
nonsignificant association between IL-6 or CRP and T2D in our study was not expected.
This could be due to the almost similar levels of BMI and insulin among participants with
and without T2D. As such, the metabolic alterations and related changes in inflammation
in participants with T2D was not severe enough to make a significant difference between
the two groups and difficult to detect. Krakoff et al.50 and Efstratiadis et al.51 investigated
the association between diabetes and IL-6 or CRP levels and reported no significant
association between these parameters after controlling for markers of obesity and other
IL-6 and CRP confounders. However, a meta-analysis of ten studies, involving 19,709
participants have shown an association between diabetes and higher levels of IL-6 and
CRP.52 These studies included either only women or only men or both and were
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conducted either within the US or outside the US. There is the need to further explore
these findings to better understand the differing results. Despite the lack of association
with T2D, IL-6 and CRP were strongly associated with known causal risk factors for
diabetes such as BMI, WC and insulin levels. Thus, the positive relationship between
chronic low-grade inflammation with adiposity measured by BMI and WC, and insulin
was observed in our study.
The results further provide evidence of an association between gender and CRP,
in congruence with previous investigations that have found higher CRP levels among
females.53 While our study participants did not differ significantly by gender for ethnicity
or diabetes status, African Americas and participants with T2D had higher percentages of
females. Females have always had higher levels of CRP than men,53 a finding that is
linked to higher BMI and WC, which was present in African Americans and participants
with T2D in our study. Our findings also revealed that age had a slight tendency of
significant association with IL-6 levels. IL-6 levels increase with age, apparently
reflecting the higher inflammation levels as age advances.47 While Haitian Americans
were older in our study, they had lower levels of IL-6 as compared to African Americans,
suggesting that this observation may be due to other factors more significant than age in
this population.
Strengths of our study include utilizing a gender-balanced, sample of two
subgroups of non-Hispanic Blacks; that are not usually compared in most studies. There
are limited studies to date on ethnic variations for MetS, T2D status and the inflammatory
burden in nonwhite populations at risk for diabetes and cardiovascular diseases. This is
the first study to the best of our knowledge that has specifically looked at MetS and its

55

components, and assessed ethnic differences in the pro-inflammatory adipocytokines, IL6 and CRP within this non-Hispanic Black ethnicity with and without T2D. Our findings
indicate significant differences in MetS components, obesity measures, and serum IL-6
and CRP levels among Haitian Americans and African Americans, thus, distinguishing
the two non-Hispanic Black groups and yields important information particularly for
Haitian Americans, a previously understudied ethnic minority subgroup.
The cross-sectional design of this is study is a limitation. As a result, causality
between ethnicity, obesity measures, MetS, T2D and the levels of pro-inflammatory
adipocytokines cannot be considered. In addition, the study population is a semiconvenience sample and not recruited by randomized selection. The sample may
therefore not be representative of Haitian Americans and African Americans living in
South Florida and as such, generalizability to the larger population may be limited. The
IL-6 concentration of 47 of the study participants was undetectable which might be that
these participants were less predisposed to increased inflammation. Since IL-6 has a short
half-life (~ 6 hours) and can be difficult to detect among particular populations using
ELISA kits, future assessment of inflammation should use IL-6 receptor as a surrogate
for IL-6 levels.
CONCLUSION
In summary, this study has important clinical and public health implications.
Inflammatory based risk for metabolic conditions may vary according to ethnicity and
other demographic variables in subgroups of non-Hispanic Blacks. The study indicates
that African Americans with MetS have higher levels of IL-6 and CRP which might be
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explained by obesity with greater BMI and WC, and hyperinsulinemia. Ethnic-centered
health interventions that focus on improving these metabolic parameters may therefore be
the key to reducing the risk for T2D and cardiovascular diseases in this population.
Future studies to determine genetic variants of the pro-inflammatory markers, and dietary
and lifestyle factors of Haitian Americans and African Americans alongside their
association with MetS may be beneficial.
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TABLE 1. Characteristics of the Participants by Ethnicity and Diabetes Status
Ethnicity
Variables
Age (years)
Female (Yes) n %

Haitian
American
(n = 230)
56.3±10.5
120 (52.2)

African
American
(n = 241)
52.5±9.5
125 (51.9)

P-value
<0.001
0.947

Diabetes status
With
Without
T2D
T2D
(n = 231)
(n = 240 )
55.9±10.2
52.6±9.8
130 (54.2)
115 (49.8)

P value
<0.001
0.341

Diabetes status (Yes) n %
120 (52.2)
120 (49.8)
0.605
Ethnicity
0.605
HA (Yes) n %
120 (50.0)
110 (47.6)
AA (Yes) n %
120 (50.0)
121 (52.4)
Smoke (Yes) n %
15 (6.5)
92 (38.2)
51 (21.3)
56 (24.4)
0.438
<0.001
Lipid meds (Yes) n %
54 (23.5)
70 (29.0)
0.170
99 (41.3)
25 (10.8)
<0.001
NSAIDs (Yes) n %
63 (27.4)
95 (39.4)
102 (42.5)
56 (24.2)
0.006
<0.001
Oral hypoglycemic meds (Yes) n %
106 (46.1)
92 (38.2)
0.082
198 (82.5)
A1C (%)
7.3±2.3
6.8±1.7
8.0±2.4
6.0±.7
0.004
<0.001
29.4±5.3
33.7±7.9
32.7±7.7
30.4±6.1
BMI (kg/m2)
<0.001
<0.001
Obese (BMI ≥30 kg/m2) n %
101 (43.9)
157 (65.1)
148 (61.7)
110(47.6)
<0.001
0.002
WC (cm)
98.5±12.5
108.4±17.6
107.3±16.9
99.6±14.2
<0.001
<0.001
FPG (mmol/L)
130.4±60.7
122.0±54.9
0.114
151.8±69.7
99.5±20.1
<0.001
TG (mg/dL)
106.7±56.0
128.2±72.7
114.3±64.5
121.1±67.2
0.269
<0.001
HDL-C(mg/dL)
53.1±14.5
49.9±13.7
51.8±14.7
51.2±13.7
0.660
0.017
SBP (mm Hg)
146.2±24.5
1 36.9±19.5
139.0±22.6
143.7±22.1
<0.001
0.024
DBP (mm Hg)
90.5±13.0
89.0±12.1
0.221
89.8±12.0
89.6±13.1
0.797
MetS (Yes) n %
160 (69.6)
176 (73.0)
0.406
215 (89.6)
121 (52.4)
<0.001
log Insulin (µIU/mL)
2.0±.7
2.4±.8
2.3±.6
2.1±.9
0.059
<0.001
log IL-6 (pg/mL)
1.69±.7
2.14±.5
1.85±.7
1.99±.6
<0.001
0.028
log CRP (mg/L)
0.50± 1.1
1.23± 1.2
0.80±1.3
0.94±1.2
0.239
<0.001
Data were expressed as mean ± SD unless otherwise indicated. Abbreviations: T2D = type 2 diabetes; NSAIDs = non-steroidal antiinflammatory drugs; BMI = body mass index; A1C = hemoglobin A1C; WC = waist circumference; FPG = fasting plasma glucose; TG
= triglycerides; HDL-C = high density lipoprotein cholesterol; SBP = systolic blood pressure; DBP = diastolic blood pressure; MetS =
metabolic syndrome; IL-6 = Interleukin 6; CRP = C-reactive protein. P-value is considered significant at <0.05.
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Fig 1. Comparison of levels of log IL-6 by metabolic syndrome and ethnicity
Data were expressed as mean ± SD. Groups with same superscript are not
significantly different assessed by ANOVA, Tukey post hoc, P<0.05.
Abbreviations: HA = Haitian Americans; AA = African Americans;
IL-6 = Interleukin-6; MetS = metabolic syndrome.
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Fig 2. Comparison of levels of log CRP by metabolic syndrome and ethnicity
Data were expressed as mean ± SD. Groups with same superscript are not
significantly different assessed by ANOVA, Tukey post hoc, P<0.05.
Abbreviations: HA = Haitian Americans; AA = African Americans;
CRP = C-reactive protein; MetS = metabolic syndrome.
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TABLE 2. Partial Correlations of log IL-6 and log CRP with MetS and Components of MetS by Ethnicity and Diabetes
Status
log IL-6 (pg/mL)
r (p-value)
Variables

log CRP (mg/L)
r (p-value)

HA
with T2D

AA
with T2D

HA
without T2D

AA
without T2D

HA
with T2D

AA
with T2D

HA
without T2D

AA
without T2D

MetS

0.14(0.122)

0.04(0.663)

0.03(0.758)

-0.05(0.611)

0.30(<0.001)

0.27(0.003)

0.13(0.189)

0.23(0.011)

WC (cm)

0.20(0.031)

0.26(0.004)

0.22(0.023)

0.09(0.354)

0.40(<0.001)

0.41(<0.001)

0.23(0.014)

0.39(<0.001)

FPG (mmol/L)

0.09(0.292)

-0.14(0.142)

0.09(0.314)

0.04(0.660)

-0.01(0.941)

0.04(0.672)

0.13(0.189)

0.14(0.118)

TG (mg/dL)

0.35(<0.001)

0.02(0.813)

0.09(0.366)

-0.07(0.467)

0.18(0.046)

0.05(0.623)

0.03(0.774)

0.08(0.375)

HDL-C (mg/dL)

-0.18(0.048)

-0.14(0.135)

-0.02(0.868)

-0.04(0.683)

-0.08(0.365)

-0.11(0.227)

0.05(0.574)

-0.12(0.177)

SBP(mm Hg)

-0.09(0.308)

-0.04(0.675)

-0.002(0.984)

-0.11(0.235)

-0.11(0.221)

-0.09(0.316)

-0.11(0.243)

0.03(0.711)

DBP (mm Hg)

-0.06(0.498)

-0.05(0.571)

-0.03(0.727)

0.05(0.621)

0.01(0.940)

0.06(0.535)

-0.07(0.456)

0.10(0.277)

log insulin(µIU/mL) 0.10(0.271)

0.02(0.868)

0.09(0.367)

0.07(0.464)

0.05(0.560)

0.19(0.036)

0.35(<0.001)

0.33(<0.001)

Data adjusted for covariates; age, gender and BMI. Abbreviations: HA = Haitian American; AA = African American; T2D = type 2 diabetes; MetS = metaboli
syndrome; WC = waist circumference; FPG = fasting plasma glucose; TG = triglycerides; HDL-C = high density lipoprotein cholesterol; SBP = systolic blood
DBP = diastolic blood pressure; IL-6 = inteleukin-6; CRP = C-reactive protein; r = correlation coefficient; P-value <0.05 (2-tail) considered significant.
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TABLE 3. Multiple Linear Regression with log IL-6 as Dependent Variable
Variables
Ethnicity
T2D status
MetS

β

SE

P-value

0.37
0.07
-0.03

0.07
0.10
0.07

<0.001
0.518
0.727

CI%
Lower
Upper
bound
bound
0.24
0.50
-0.14
0.27
-0.17
0.12

Model Summary: F (1,460) = 0.122, P = 0.727; adj R2 = 0.137; Covariates: Age (P = 0.054); Gender (P = 0.592); BMI (P = 0.001);
Smoke (P = 0.208); NSAIDs (P = 0.816); Diabetes medications (P = 0.643); Lipid medications (P = 0.662); Abbreviations: IL-6 =
Interleukin 6; β = B coefficient; SE = standard error; T2D = type 2 diabetes; MetS = metabolic syndrome.

68

TABLE 4. Multiple Linear Regression with log CRP as Dependent Variable
Variables
Ethnicity
T2D status
MetS

β
0.47
0.09
0.34

SE

CI%

P-value

0.12
0.19
0.14

<0.001
0.651
0.012

Lower
bound
0.24
-0.29
0.07

Upper
bound
0.71
0.46
0.60

Model Summary: F (1,460) = 6.332, P = 0.012; adj R2 = 0.227; Covariates: Age (P = 0.559); Gender (P = 0.001); BMI (P<0.001); Smoke
(P = 0.862); NSAIDs (P = 0.360); Diabetes medications (P = 0.237); Lipid medications (P = 0.596). Abbreviations: CRP = C-reactive
protein; β = B coefficient; SE = standard error; T2D = type 2 diabetes; MetS = metabolic syndrome.
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CHAPTER IV: SERUM CHEMERIN AND OMENTIN IN HAITIAN AND
AFRICAN AMERICANS WITH AND WITHOUT TYPE 2 DIABETES
ABSTRACT
Background: Recently, chemerin and omentin have been identified as novel
adipocytokines that are associated with obesity, insulin action and the development of
type 2 diabetes (T2D). The circulating levels of chemerin and omentin and their
association with T2D among non-Hispanic Black ethnic subgroups have not been studied.
This study was conducted to determine whether the levels of chemerin and omentin are
altered by ethnicity and diabetes status. Methods: The study included 429 participants,
225 without T2D and 204 with T2D (214 Haitian Americans and 215 African
Americans). African Americans were recruited through mailing lists and Haitian
Americans through multiple community sources. After informed consent, information on
socio-demographic variables and clinical data were obtained. Serum levels of chemerin
and omentin were measured by ELISA and the homeostasis model assessment version 2
was used to estimate insulin sensitivity (HOMA2-IS).
Results: Haitian Americans with T2D had significantly lower serum chemerin levels (P
<0.001) and significantly higher serum omentin levels (P = 0.023) compared to African
Americans with T2D. Diabetes status was negatively associated with chemerin (B = 41.35, SE = 18.28, P = 0.024), but not significantly associated with omentin (B = -85.02,
SE = 56.86, P = 0.136) in the separate models, after adjusting for covariates. HOMA2-IS
was inversely associated with chemerin (B = -0.229, SE = 0.11, P = 0.030), but not with
omentin (B = 0.11, SE = 0.33, P = 0.745). Conclusion: Haitian Americans with T2D had
lower chemerin and higher omentin levels compared to African Americans with T2D.
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The lower percentage of obesity in Haitian Americans may explain the lower chemerin
and higher omentin. The unexpected inverse association of chemerin with diabetes status
may have been due to the residual confounding effects of medications used mainly by
participants with T2D. The relationship between chemerin and omentin in T2D should be
further investigated in prospective studies and drug-naïve individuals.
INTRODUCTION
Type 2 diabetes (T2D) is a heterogeneous metabolic disorder characterized by
impaired insulin sensitivity and/or action and a resulting chronic hyperglycemia.1-3
Worldwide, T2D has become a public health concern. In the United States (US) alone,
about 29 million are diagnosed with the disease, accounting for 245 billion dollars in
annual healthcare costs.4-5 Moreover, important ethnic disparities in T2D prevalence and
outcomes have been reported.6-7 While the rate of T2D has increased across all ethnic
groups, non-Hispanic Blacks have had almost a doubling of prevalence of diagnosed
diabetes since 1988.8 According to the 2014 National Diabetes Statistics Report, the
prevalence of T2D was 13.2% among non-Hispanic Blacks in 2012; 1.1 times and 1.7
times higher than in Hispanics and non-Hispanic Whites, respectively.4 Thus, nowadays
the focus on the effort to reduce the prevalence of T2D should be to conduct studies with
respect to ethnic differences, particularly within the non-Hispanic Black population.9-10 It
is suggested that a higher susceptibility to inflammation may account for the increased
prevalence of T2D among non-Hispanic Blacks.11-12
Type 2 diabetes is considered a state of chronic low-grade inflammation, and that
inflammation is suggested to initiate and contribute to the progression of T2D.12-14 It is

71

well recognized that obesity and insulin resistance are prominent factors associated with
the chronic low-grade inflammation and ultimately the development of T2D.12-15 The
altered secretion of adipose-derived peptides (adipocytokines) have considerable
influence on glucose metabolism in the main target tissues (adipose tissue, muscle and
liver) of insulin.15-18 Chemerin is a recently discovered pro-inflammatory adipocytokine
that have been shown to inhibit insulin signaling through the activation of key
inflammatory modulators such as the nuclear factor-kB signaling pathways.15-19 The
consequences of these processes are perpetuation of inflammation and decreased insulin
sensitivity. Chemerin is secreted as an inactive prochemerin and cleaved through serine
protease activity to the active chemerin.20 Chemerin levels are increased in obese
individuals and states of impaired insulin sensitivity, insulin resistance and metabolic
syndrome.20-21 Thus, the role of chemerin in these processes, may explain the relationship
between obesity, insulin action and T2D. Another candidate, omentin, a newly identified
adipocytokine is involved in glucose and lipid metabolism.22-23 Omentin is a novel
adipocytokine with insulin-sensitizing effects similar to adiponectin.23 Obesity, decreases
visceral adipose tissue expression of the anti-inflammatory adipocytokine omentin.24 In
several studies, omentin was shown to be significantly decreased in obese individuals and
those with T2D.24-25
Previous studies on adipocytokines and obesity-related disorders have been
focused on TNF-α, leptin, resistin and adiponectin.26-27 Moreover, studies involving
chemerin and omentin have been conducted mostly among non-Hispanic Whites and
other Hispanic ethnic subgroups.20,28-29 To our knowledge, to date no studies have
assessed the novel adipocytokines, chemerin and omentin among non-Hispanic Black
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subgroups. Considering the burden of disease among non-Hispanic Blacks with regards
to T2D, it is worth understanding the levels of chemerin and omentin and identify other
factors associated with T2D in this population. The purpose of this study was to
determine whether the levels of chemerin and omentin differ by ethnicity and diabetes
status and we also investigated the relationship of diabetes status with chemerin and
omentin.
STUDY SUBJECTS AND DESIGN
This study was an ancillary study which generated data on adipocytokines from
stored blood samples of the parent study that compared cardiovascular risk factors in
non-Hispanic Blacks with and without T2D. The objective of this cross-sectional study
was to determine the levels of chemerin and omentin in Haitian Americans and African
Americans with and without T2D and to investigate their relationship to diabetes status.
Between the period of 2008-2010, study subjects were recruited in South Florida, from
the Miami- Dade and Broward Counties. African American participants were recruited
randomly from two mailing lists provided by Knowledge Base Marketing, Inc.,
Richardson, TX, USA. The company generated the list of addresses from several
databases of African Americans with and without T2D. Approximately 7550 letters were
mailed to African Americans to request their participation. From the letters that were
delivered, 4% (n = 256) of the participants responded. Recruitment of Haitian Americans
(n = 259) was from multiple community based sources since a similar database of mailing
addresses was unavailable for this group. The recruitment strategies included: i)
placement of print advertisements in local Haitian supermarkets, churches, and
restaurants ii) distribution of flyers to Florida International University (FIU) community
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iii) request to local diabetes educators and community health professionals and iv) airing
of announcements on Creole radio stations. Telephone interviews were conducted for
respondents who expressed interest in the study. During the phone calls, the purpose of
the study was fully explained and final eligibility was assessed (i.e., age – ≥35 years,
gender and self-identified ethnicity – African American and Haitian American).
Additionally, T2D status was ascertained based on fasting plasma glucose and
hemoglobin A1C, diabetes duration and initial treatment modalities. Respondents with
the following conditions were excluded: kidney failure, hepatitis, HIV and cancer. The
study protocol obtained ethical approval from the Institutional Review Board (IRB) at
FIU. Eligible respondents were invited for an enrollment visit at the Human Nutrition
Laboratory at FIU. Participants were instructed to complete an overnight fast (at least 8
hours) prior to blood collection, during which they could drink only water, refrain from
smoking and any unusual exercise. Informed consent in English or Creole with IRB
ethical clearance was obtained from participants after they understood and agreed to the
terms on the form. Eight Haitian Americans and 4 African Americans who self-reported
as having no T2D, yet whose laboratory results showed high values of fasting plasma
glucose (FPG) and glycated hemoglobin (A1C) for diabetes were reclassified as having
diabetes and referred to their physicians. Participants (n = 87) with missing values and
outliers for chemerin, omentin and HOMA2-IS were excluded. Data was available for
429 participants, 225 without T2D and 204 with T2D (214 Haitian and 215 African
Americans) for final statistical analysis.
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METHODS
Study participants responded to a validated self-reported questionnaire. Trained
interviewers administered in depth standardized questionnaires to participants to
complete. Socio-demographic information comprised questions related to age, gender,
smoking status, and medications used. Height and weight were measured using a SECA
balance scale (Seca Corp, Columbia, MD). Body mass index (BMI) was calculated as
weight in kg divided by height in m2.
Clinical and laboratory assessments
Following an 8-hour overnight fast, twenty milliliters of venous blood was
collected in a Vaccutainer Serum Separator tube by a trained and certified phlebotomist
using standard methods. Blood samples were centrifuged at 2500 RPM for half an hour
after coagulation. The separated serum was aliquoted into 3 labeled plastic tubes. Two
were designated for glucose determination and lipid panel analysis. The third aliquot was
stored at -700C for subsequent analyses. Glucose levels were measured by hexokinase
enzymatic methods (Laboratory Corporation of America, FL, USA). Hemoglobin A1C
percentages were assayed in whole blood samples applying the Roche Tina Quant
method (Laboratory Corporation of America, FL, USA). Fasting serum insulin levels
were determined with enzyme-linked immunosorbent assay (ELISA) using commercially
available kits (Millipore, St Charles, MS, USA).
Chemerin levels in serum were measured at the Human Nutrition Laboratory at
FIU with ELISA using microtitration plates pre-coated with polyclonal anti-human
chemerin antibody according to manufacturer’s protocol (BioVendor LLC, Candler, NC,
USA). Briefly, 100µl of standards, quality controls, dilution buffer (blank) and diluted
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samples (100x – 5µl sample plus 495µl dilution buffer) were pipetted in duplicates into
wells on the microplate. After an hour of incubation at room temperature (shaking at 300
RPM) followed by washing, 100 µl biotin labelled antibody solution was added and
incubated with the bound chemerin for another hour. After a second washing step, 100 µl
streptavidin-HRP conjugate was added and incubated for half an hour at room
temperature (shaking at 300 RPM). The last washing step was performed and the residual
conjugate was allowed to react with the 100 µl of substrate solution
(tetramethylbenzidine). The reaction process was stopped by addition of 100 µl of an
acidic stop solution. The absorbance of the resulting product was measured at 450nm
with a spectrophotometer. A microplate reader capable of creating a standard curve
plotted the mean absorbance values against the chemerin concentrations of standards. The
software used the standard curve to determine the concentrations of the unknown diluted
samples multiplied by the dilution factor to obtain the actual amount of serum chemerin.
The sensitivity of the ELISA assay was 0.1 ng/ml and the range was 0.1–8 ng/ml (10–800
ng/ml with dilution factor). The intraassay and interassay coefficients of variation were
both less than 10%.
Serum omentin levels were determined in the Human Nutrition Laboratory at FIU
using human omentin-1 detection kit (ELISA, BioVendor LLC, Candler, NC, USA)
according to manufacturer’s protocol. Serum samples were diluted and assayed using
microplates pre-coated with polyclonal anti-human omentin-1 antibody. Briefly, 100µl of
standards, quality controls, dilution buffer (blank) and diluted samples (40x – 6µl sample
plus 234µl dilution buffer, or 60x further dilution for samples that exceeded 2560 ng/ml)
were pipetted in duplicates into wells on the microplate. After 2 hours of incubation at
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370C followed by washing, 100 µl biotin labelled antibody solution was added and
incubated with the bound omentin for half an hour. After a second washing step, 100 µl
streptavidin-HRP conjugate was added and incubated at 370C for half an hour at room
temperature. The last washing step was performed and the residual conjugate was
allowed to react with the 100 µl of substrate solution (tetramethylbenzidine). The reaction
process was stopped by addition of 100 µl of an acidic stop solution. The absorbance of
the resulting product was measured at 450nm with a spectrophotometer. A microplate
reader capable of creating a standard curve plotted the mean absorbance values against
the omentin concentrations of standards. The software used the standard curve to
determine the concentrations of the unknown diluted samples multiplied by the dilution
factor to obtain the actual amount of serum omentin. The intraassay and interassay
coefficients of variation were both less than 10%. The sensitivity of the ELISA assay was
0.5 ng/ml and the range was 0.5–64 ng/ml (80–2560 ng/ml with dilution factor).
Calculation of insulin sensitivity (HOMA2-IS)
The Oxford University HOMA2 calculator was used to calculate insulin
sensitivity index as previously described.30 The model determines insulin sensitivity
index (HOMA2-IS) from paired fasting plasma glucose and radioimmunoassay insulin
across a range of 1-2,200 pmol/l for insulin, and 1-25 mmol/l for glucose.
Data Analysis
Statistical analyses were conducted with SPSS version 21 (IBM Corporation,
Chicago, IL, USA). The Kolmogorov-Smirnov test was used to assess the normality of
the distribution of the data. A Student’s t-test was used for continuous variables and χ2
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tests for categorical variables to compare participants by ethnicity and diabetes status.
The analysis of variance (ANOVA) was used to compare serum levels of chemerin and
omentin according to BMI categories (normal weight: BMI<25kg/m2, overweight: BMI
25kg/m2 - < 30kg/m2 and obese: BMI ≥30kg/m2), followed by Tukey’s post hoc tests.
The relationships between variables were analyzed by multiple linear regression
controlling for the covariates including age, gender, BMI, ethnicity (Haitian
Americans/African Americans), smoke (yes/no), lipid lowering drugs (yes/no), nonsteroidal anti-inflammatory drugs {NSAIDs} (yes/no), oral hypoglycemic medications
(yes/no) and HOMA2-IS. The serum concentrations of chemerin and omentin were used
as dependent variables in separate models. A P-value of <0.05 was considered to be
statistically significant.
RESULTS
Tables 1 and 2 show for the characteristics of the participants included in this
study according to diabetes status and diabetes status by ethnicity.
The mean age of participants with T2D was 56.0±10.2 years and those without T2D was
52.1±9.7 years (Table 1). The percentages for the three BMI categories were significantly
different between participants with T2D as compared to participants without T2D. The
use of medications (lipid lowering drugs and NSAIDs) in participants with T2D were
highly significant than in participants without T2D (P<0.001). Fasting plasma glucose
and A1C in participants with T2D were significantly higher (P<0.001) than in
participants without T2D. Moreover, fasting insulin levels and HOMA2-IS were not
significantly different between participants with and without T2D. Serum chemerin and
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omentin levels were not significantly different in participants with T2D as compared to
participants without T2D. There was no significant difference by gender between
participants with T2D as compared to participants without T2D. The percentage of
smokers in participants with T2D was comparable to that of participants without T2D.
Table 2 shows that in the group with diabetes, Haitian Americans with T2D were
significantly older (P=0.009), had lower BMI (P<0.001), lower percentage of smokers
(P<0.001), higher intake of oral hypoglycemic medications (P=0.002), higher A1C
(P<0.009), higher HOMA2-IS (P<0.001), lower chemerin levels (P<0.001) and higher
omentin levels (P=0.023) than did African Americans with T2D. There were significant
differences also in age, BMI, FPG, A1C, insulin levels, HOMA2-IS and medication use
by diabetes status and ethnicity. African Americans without T2D were significantly
younger (P=0.013), had higher insulin levels (P=0.006) and higher percentage of
smokers (P<0.001). Haitian Americans without T2D had significantly higher mean FPG
(105.1±29.0) and A1C (6.2±0.9). Serum chemerin levels were significantly lower in
Haitian Americans without T2D (P<0.001), whereas omentin levels were slightly higher
in African Americans without T2D, however not significantly. There was no significant
differences in BMI and HOMA2-IS between Haitian and African Americans without
T2D. Moreover, African Americans without T2D had higher, but not significantly intake
of lipid medications and NSAIDs compared to Haitian Americans without T2D.
We further used ANOVA to analyze the difference in means of serum chemerin
and omentin levels among participants with and without T2D by BMI categories; the data
was classified as normal weight: BMI<25kg/m2, overweight: BMI 25kg/m2 - <30kg/m2
and obese: BMI ≥30kg/m2 (Table 3). Among participants with T2D, those with normal
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weight had significantly lower chemerin and higher omentin levels compared with those
who were obese. There was no significant difference in chemerin and omentin levels
between normal and overweight and overweight and obese individuals. Among
participants without T2D, there was no significant difference in mean serum chemerin
and omentin levels with BMI categories.
Tables 4 and 5 show the multiple linear regressions run with chemerin and
omentin as dependent variables in separate models. Diabetes status was negatively
associated with chemerin (B = -41.35, SE = 18.28, P = 0.024), but not associated with
omentin levels (B = -85.02, SE = 56.86, P = 0.136). African American (B = 38.48, SE =
11.59, P = 0.001), having a lower HOMA2-IS (B = -0.23, SE = 0.11, P = 0.030), being
older (B = 1.37, SE = 0.51, P = 0.008) and being female (B = -21.14, SE = 10.15, P =
0.038) were associated with chemerin. Omentin levels were negatively associated with
BMI (B = -6.64, SE = 2.66, P = 0.013) and positively associated with age (B = 6.69, SE =
1.59, P <0.001). A test of the interaction effect between ethnicity and diabetes status
showed that the interaction term was not significant.
DISCUSSION
To date, no studies have characterized the novel adipocytokines, chemerin and
omentin, among non-Hispanic Black subgroups, a high-risk population for the
development of type 2 diabetes (T2D). Thus, in this study, we determined the levels of
serum chemerin and omentin in Haitian Americans and African Americans with and
without T2D and assessed their relationship with T2D, controlling for important
covariates. The results of the present study surprisingly revealed a significant negative
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association between diabetes status and chemerin. Nonsignificant negative association
was found with omentin and diabetes status. Chemerin is an adipose-tissue derived
adipocytokine that has been shown to be elevated in states of obesity-related disorders
such as T2D.19,31-32 Recently, chemerin was identified as a pro-inflammatory
adipocytokine that plays a role in inflammation and metabolism.33-34 It is therefore
suggested that chemerin may provide a link between chronic low-grade inflammation and
T2D. Our findings on chemerin are in contrast to that of El-Mesallamy et al.35 who
reported that chemerin levels were significantly increased in participants with T2D
compared to participants without T2D. However, our findings are in line with that of
Bozaoglu et al.19 which failed to show a significant difference in chemerin levels in
adults with compared to without T2D. The non-significant difference in chemerin levels
between participants with and without T2D and the greater effect of association for
participants without T2D than participants with T2D may be due to the fact that a higher
proportion of the participants with T2D were on diabetes medications. The medications
for diabetes have been reported to significantly decrease chemerin levels in diabetic
patients. For example in a study among women with polycystic ovarian syndrome,
metformin, an oral hypoglycemic agent, was shown to decrease circulating chemerin
levels with a simultaneous decrease in insulin resistance.36
Omentin is a novel polypeptide hormone which triggers Akt/protein kinase B
phosphorylation and insulin stimulated glucose uptake in human adipocytes in vitro.23
Omentin is considered an anti-inflammatory modulator and may have a protective role in
T2D.37 Although our findings demonstrated that participants without T2D had higher
omentin levels, this association was not significant and might be that a lowering of
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chemerin levels by diabetes medications caused a reciprocal increase in omentin levels in
participants with T2D. However, the levels may not have been pronounced to detect a
significant difference. However, previous studies showed that omentin levels were
increased in healthy individuals compared with adults with T2D and found a significant
negative association.35,37-38 The roles of omentin and chemerin in regulating metabolic
function still need to be fully elucidated in future investigations among drug-free subjects
to exclude any residual confounding effects of medications.
Chemerin levels are positively associated with obesity, but negatively associated
with insulin sensitivity.31,34,39 Chemerin is secreted by mature adipocytes within adipose
tissue.19 Obesity leads to hypertrophy of adipocytes which in turn increases chemerin
secretion and contributes to inflammation. Previous studies have shown that chemerin
may regulate insulin signaling and glucose metabolism.40-41 In vitro studies in 3T3-L1
adipocytes revealed that chemerin impaired insulin sensitivity and induced insulin
resistance in muscle cells.41 Impaired insulin sensitivity is a major risk factor for the
development of T2D. In addition, administration of chemerin to obese diabetic mice
resulted in decreased tissue glucose uptake and worsened glucose intolerance.32 In
accordance, serum chemerin levels were positively associated with BMI, although a
nonsignificant one which might be due to the effect of medications on chemerin levels as
already discussed above, since most of the obese individuals in our sample also had T2D.
Other earlier studies also reported no significant association between serum chemerin and
BMI.34 Additionally, in the present study, chemerin was negatively associated with
insulin sensitivity, a finding in line with the studies by Kim et al.31 that showed a negative
association between chemerin and insulin sensitivity in adults with T2D. Other studies
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have demonstrated conflicting results, with the study by Takahashi et al.41 reporting that
increased levels of chemerin stimulated insulin sensitivity. Thus, these conflicting
findings warrants a need to clarify the mechanisms by which chemerin regulates glucose
homeostasis.31,41 Omentin was negatively associated with BMI and positively associated
with insulin sensitivity in the present study. Omentin is secreted by the visceral adipose
tissue and is decreased in obese patients, while it is involved in improving insulin
sensitivity.23 Recently, in a study conducted by El-Mesallamy35 in Egyptian adults
comparing omentin levels between those with T2D and healthy controls, omentin levels
were negatively associated with obesity. Similarly, Tan et al.42 found a negative
correlation between BMI and omentin levels. However, the nonsignificant differences for
chemerin and omentin levels found between normal weight, overweight or obese in
participants without T2D and between overweight and obese individuals in participants
with T2D might be due to the smaller sample sizes for the normal weight and overweight
group. It is possible that the significant differences in chemerin and omentin levels found
between normal weight and obese patients among participants with T2D may have
occurred by chance.
We have also demonstrated that Haitian Americans with T2D had significantly
lower levels of chemerin and significantly higher levels of omentin compared with
African Americans with T2D. This could be due to the lower BMI and higher insulin
sensitivity observed in Haitian Americans compared to a higher BMI and impaired
insulin sensitivity in African Americans. A lower BMI has been associated with
increased insulin sensitivity which results in lowered insulin resistance.31 Haitian
Americans without T2D compared to African Americans without T2D, had significantly
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lower levels of chemerin and surprisingly, slightly lower, but nonsignificant levels of
omentin. Also in regression analysis, chemerin was associated with African American
ethnicity which is expected. It is not surprising that the association of Haitian American
ethnicity with omentin was not significant, which may have been due to low levels of
omentin found among Haitian Americans. An explanation may be the higher percentage
of lipid lowering drugs and NSAIDs use by African Americans which decreased
possibility of significant differences being observed. An alternative explanation may be
due to differences in particular metabolic characteristics between Haitian Americans and
African Americans. The influence of certain unique characteristics such as acculturation,
genetics and other environmental factors cannot be ruled out. The lack of existing data on
the two ethnicities with regards to chemerin and omentin make it difficult to compare and
contrast our findings with the literature and draw substantial conclusions. It is necessary
for additional studies to be conducted in order to make further conclusions.
The limitation of this study is the cross-sectional nature which did not allow
causality to be considered. In addition, the study population is a semi-convenience
sample and not recruited by randomized selection. Moreover, genetic and acculturation
factors may be possible influential variables on chemerin and omentin that were not
considered. As such, the sample may not be representative of Haitian Americans and
African Americans and generalizability to the general population may be limited. The
serum chemerin levels measured are a reflection of the total level since the ELISA did
not allow for the chemerin variants to be distinguished. Despite the limitations, this study
has for the first time assessed novel adipocytokines, chemerin and omentin in two distinct
non-Hispanic subgroups, which allows important ethnic differences in metabolic
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processes to be revealed. These results provide new opportunities for designing ethnic
centered preventive strategies and targets for the treatment of T2D, particularly in nonHispanics who are at high risk for T2D and its related complications. The serum levels of
chemerin and omentin in this study are similar to those found in other studies using the
same ELISA kit or studies conducted in participants with and without T2D and other
disorders.35,43-44
CONCLUSION
In conclusion, Haitian Americans with T2D had lower chemerin and higher
omentin levels compared to African Americans with T2D. These findings support the
need to conduct studies of metabolic disorders based on ethnicity, particularly for nonHispanic Blacks who are highly susceptible to T2D and its associated outcomes.
Moreover, important factors such as acculturation, genetics and other environmental
factors may be unique to each ethnic subgroup and influence disease risk factors and
progression of T2D. The relationship of chemerin and omentin with T2D should be
further investigated in prospective studies.
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TABLE 1. Characteristics of the Participants by Diabetes Status
Variables
Age (years)
Female n (%)
Ethnicity
HA n (%)
AA n (%)
*BMI categories (kg/m2)
Normal weight n (% )
Overweight n (%)
Obese n (%)
Smoke n (%)
Lipid lowering drugs n (%)
NSAIDs n (%)
Oral hypoglycemic meds n (%)
A1C (%)
FPG (mmol/L)
Insulin (µIU/mL)
HOMA2-IS
Chemerin (ng/mL)
Omentin (ng/mL)

Diabetes status
With
Without
T2D
T2D
(n = 204)
(n = 225)
56.0±10.2
52.1±9.7
110(53.9)
114(50.7)
99(48.5)
105(51.5)

25(12.3)
58(28.4)
121(59.2)
42(20.6)
85(41.7)
84(41.2)
168(82.4)
8.1±2.3
150.9±65.1
11.8±9.2
86.9±50.1
334.3±103.2
723.1± 327.4

115(51.1)
110(48.9)
36(16.0)
89(39.6)
100(44.4)
51(22.7)
24(10.7)
55(24.4)
6.0±0.8
101.0±23.9
11.4±8.2
93.6±51.9
348.5±110.1
752.2±315.0

Overall
P-value
<0.001
0.500
0.593
0.009
0.602
<0.001
<0.001
<0.001
<0.001
0.666
0.181
0.170
0.349

(n = 429)
53.9±10.1
224(52.2)
214(49.9)
215(50.1)
61(14.2)
147(34.3)
221(51.5)
93(21.7)
109(25.4)
139(32.4)
168(39.2)
7.0±1.9
124.8±54.2
11.6±8.7
90.5±51.1
341.7±107.0
738.3±320.9

Data were expressed as mean ± SD unless otherwise indicated. Abbreviations: T2D = type 2 diabetes; HA = Haitian Americans; AA = African
Americans; BMI = body mass index; NSAIDs = non-steroidal anti-inflammatory drugs; A1C = hemoglobin A1C; FPG = fasting plasma glucose;
HOMA2-IS = homeostasis model assessment version 2 of insulin sensitivity. *BMI categories: Normal weight: BMI<25kg/m2, Overweight: BMI
25kg/m2 - <30kg/m2 and Obese: BMI ≥30kg/m2.
P-value is considered significant at <0.05.

91

TABLE 2. Characteristics of the Participants by Ethnicity and Diabetes Status
Variables

With T2D
Haitian
African
American
American
(n = 99)
(n = 105)
57.9±9.7
54.2±10.3
54(54.5)
56(53.3)

Age (years)
Female n (%)
*BMI categories (kg/m2)
Normal weight n (%)
22(22.2)
Overweight n (%)
38(38.4)
Obese n (%)
39(39.4)
Smoke n (%)
5(5.1)
Lipid lowering drugs n (%)
38(38.4)
NSAIDs n (%)
31(31.3)
Oral hypoglycemic meds n (%) 90(90.9)
A1C (%)
8.5±2.6
FPG (mmol/L)
154.2±62.4
Insulin (µIU/mL)
9.4±7.2
HOMA2-IS
100.9±51.9
Chemerin (ng/mL)
310.2±96.9
Omentin (ng/mL)
777.1±367.1

Pvalue
0.009
0.862
<0.001
3(2.9)
20(19.0)
82(78.1)
37(35.2)
<0.001
47(44.8)
0.356
53(50.5)
0.005
78(74.3)
0.002
7.6±1.9
0.009
147.9±67.7
0.494
14.1±10.3 <0.001
73.8±44.7 <0.001
357.1±104.2 <0.001
672.1±277.2
0.023

Without T2D
Haitian
African
American
American
(n = 115)
(n = 110)
53.7±10.5
50.5±8.5
57(49.6)
57(51.8)
23(20.0)
49(42.6)
43(37.4)
7(6.1)
9(7.8)
23(20.0)
6.2±0.9
105.1±29.0
9.9±5.3
97.9±50.3
318.1±94.9
716.3±319.5

Pvalue
0.013
0.735
0.063
13(11.8)
40(36.4)
57(51.8)
44(40.0)
<0.001
15(13.6)
0.158
32(29.1)
0.113
5.9±0.5
0.025
96.7±15.9
0.008
12.9±10.2
0.006
89.1±53.4
0.202
380.3±116.2 <0.001
789.7±307.3
0.080

Data were expressed as mean ± SD unless otherwise indicated. Abbreviations: T2D = type 2 diabetes; HA = Haitian Americans;
AA = African Americans; BMI = body mass index; NSAIDs = non-steroidal anti-inflammatory drugs; A1C = hemoglobin A1C;
FPG = fasting plasma glucose; HOMA2-IS = homeostasis model assessment version 2 of insulin sensitivity.
*BMI categories: Normal weight: BMI<25kg/m2, Overweight: BMI 25kg/m2 - <30kg/m2 and Obese: BMI ≥30kg/m2.
P-value is considered significant at <0.05.
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BMI Categories
Participants with T2D
Variables
BMI categories(kg/m2)
Chemerin (ng/mL)
Omentin (ng/mL)

Normal weight
(n = 25)
<25
292.6±102.1a
913.1±467.7a

Overweight
(n = 58)
25-<30
320.0±107.5ab
742.7±306.1ab

Obese
(n = 121)
≥30
349.8±98.7b
674.4±288.1b

P- value

Obese
(n = 100)

P-value

≥30
367.2±119.9
715.1±302.6

–
NS
NS

–
0.030
0.002

Participants without T2D
Normal weight
(n = 36)
BMI categories (kg/m2)
Chemerin (ng/mL)
Omentin (ng/mL)

<25
336.7±105.4
825.6±367.8

Overweight
(n = 89)
25-<30
332.4±97.8
764.1±303.1

Data are expressed as mean ± SD unless otherwise indicated. P-value is considered significant at <0.05. Abbreviations: T2D = type 2 diabetes;
BMI = body mass index; NS = no significant differences between normal weight, overweight and obese or overweight and obese individuals.
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TABLE 4. Association between Chemerin and Diabetes Status – Multiple Linear Regression Analysis
Variables
Diabetes status
Ethnicity
HOMA2-IS
BMI
Age
Gender
Smoke
Lipid lowering drugs
NSAIDs
Oral hypoglycemic meds

B
-41.35
38.48
-0.23
1.22
1.37
-21.14
24.81
15.56
21.31
9.39

SE
18.28
11.59
0.11
0.86
0.51
10.15
13.24
12.89
11.39
19.06

β
-0.19
0.18
-0.11
0.08
0.13
-0.09
0.09
0.06
0.09
0.04

t
-2.26
3.32
-2.18
1.43
2.68
-2.08
1.87
1.21
1.87
0.49

P-value
0.024
0.001
0.030
0.153
0.008
0.038
0.062
0.228
0.062
0.622

Adjusted R2 of model: 12.9% of independent contribution of diabetes status (t =-2.26, P=0.024). Abbreviations: HOMA2-IS =
homeostasis model assessment version 2 of insulin sensitivity; BMI = body mass index; NSAIDs = non-steroidal anti-inflammatory drugs;
B = unstandardized coefficients; SE = standard error; β = standardized coefficient. P-value is considered significant at <0.05.
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TABLE 5. Association between Omentin and Diabetes status – Multiple Linear Regression Analysis
Variables

B

Diabetes status
-85.02
Ethnicity
52.71
HOMA2-IS
0.11
BMI
-6.64
Age
6.69
Gender
15.55
Smoke
-30.92
Lipid lowering drugs
73.80
NSAIDs
4.56
Oral hypoglycemic meds 26.56

SE

β

56.86
36.07
0.33
2.66
1.59
31.57
41.18
40.13
35.43
59.29

-0.13
0.08
0.02
-0.14
0.21
0.02
-0.04
0.10
0.01
0.04

t
-1.50
1.46
0.33
-2.49
4.19
0.49
-0.75
1.84
0.13
0.45

P-value
0.136
0.145
0.745
0.013
<0.001
0.623
0.453
0.067
0.898
0.654

Adjusted R2 of model: 6.3% of independent contribution of diabetes status (t =-1.50, P=0.136). Abbreviations: HOMA2-IS = homeostasis
model assessment version 2 of insulin sensitivity; BMI = body mass index; NSAIDs = non-steroidal anti-inflammatory drugs; B =
unstandardized coefficients; SE = standard error; β = standardized coefficient. P-value is considered significant at <0.05.
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CHAPTER V: ASSOCIATION OF LEPTIN WITH BMI AND INSULIN RESISTANCE
IN HAITIAN AND AFRICAN AMERICANS WITH AND WITHOUT TYPE 2
DIABETES
ABSTRACT
Background: Obesity has become a worldwide epidemic and non-Hispanic Blacks are
disproportionately affected. Leptin is an adipose tissue derived peptide that is considered
both structurally and functionally as a pro-inflammatory adipocytokine. Leptin has been
associated with obesity, insulin resistance and type 2 diabetes (T2D). Ethnic differences
in metabolic profile even within the same ethnicity may affect leptin levels and disease
outcomes. The purpose of our study was to determine the variation in serum leptin levels
in Haitian and African Africans and assess the association of leptin levels with body mass
index (BMI) and insulin resistance. Methods: In 413 participants, 213 Haitian Americans
and 200 African Americans (197 with T2D and 216 without T2D), fasting blood samples
and clinical data were obtained, and socio-demographic data were collected using
standardized questionnaires. Serum leptin levels and insulin resistance measures were
analyzed by ELISA and HOMA-2-IR, respectively. Results: The serum log leptin levels
in Haitian American males and females were significantly lower (P<0.05) than those in
African American males and females. Haitian Americans with T2D had significantly
lower serum log leptin levels (P=0.024) than did African Americans with T2D. Log
leptin levels were significantly associated with BMI (P<0.001) and HOMA2-IR
(P=0.015) in males without T2D, whereas in males with T2D and females with and
without T2D, leptin was associated with only BMI (P<0.001) as a primary independent
variable. Conclusion: The lower leptin levels in Haitian Americans may be due to

96

favorable metabolic profile including lower obesity and insulin resistance. The ethnic
differences may also be attributable to genetic variation and differences in lifestyle,
environmental and acculturation factors which may affect risk of disease. Future studies
should focus on the association of these factors with leptin levels in the two ethnic
subgroups. In addition, these findings may help identify individuals at risk for T2D
across adiposity and make an important contribution in designing ethnic centered
interventions to prevent T2D.

INTRODUCTION
Obesity, defined as body mass index (BMI) of ≥30 kg/m2, has become a major
health concern.1-3 Approximately, one-third of the United States adult population is
obese.3 Between 1997-2007 and 2011-2012, there has been a significant increase in the
prevalence of obesity from 27% to 35% for both men and women and across all age
groups.3-4 Obesity is one of the major causes of preventable death and is closely related to
insulin resistance, which may lead to type 2 diabetes (T2D).2,5-7 Type 2 diabetes is a
major cause of morbidity and mortality in the United States.8 Type 2 diabetes and its
health-related outcomes pose an immense burden both on individuals with the disease
and on public health systems.9 The prevention of T2D and its associated outcomes,
particularly cardiovascular risk has become a public health priority. Anti-diabetes efforts
to reverse the increasing prevalence of T2D is threatened by a growing epidemic of
obesity.2 While insulin resistance is widely accepted as the core process in the
development of T2D, new concepts indicate initial inflammatory responses.10-11 Several
peptides released from white adipose tissue with excess adiposity have been implicated in
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the coexistence of obesity and T2D. Leptin is one of the peptides that influences energy
intake, inflammation and insulin resistance.12-13
Leptin an adipocytokine and a product of the ob gene regulates body weight by
acting centrally to reduce energy intake.14-17 Additionally, leptin modulates glucose and
fat homeostasis.12,15 In humans, circulating levels of leptin are directly proportional to
BMI or body fat percentage and high levels of leptin in obese individuals suggests leptin
resistance in the central nervous system.15,18 Previous studies show that obesity-induced
leptin resistance activates the c-Jun NH(2)-terminal kinase (JNK) and inhibitor of nuclear
factor kappa-B kinase subunit beta (IKKβ) inflammatory pathways.13 Moreover, leptin
has structural similarity to interleukin-6 (IL-6) and may subsequently increase C-reactive
protein (CRP) levels.19-21 Further, leptin stimulates macrophages and monocytes to
produce IL-6 and TNF-α, pro-inflammatory adipocytokines well-recognized to affect
insulin sensitivity and induce insulin resistance.20 The reports of associations of leptin
with other pro-inflammatory adipocytokines, insulin resistance and prevalence of T2D
indicate leptin as a strong determinant of obesity and its complications.22 Serum leptin
levels also show marked gender differences, with higher concentrations in women than in
men at all levels of BMI.23 Apart from gender, existing studies also show that lifestyle
factors such as diet and smoking may affect serum leptin levels.22,24-25 For example,
vitamin D is an immune-modulator which may attenuate inflammation, enhance insulin
sensitivity and thus is inversely associated with leptin levels.25 Cigarette smokers, on the
other hand have lower leptin levels compared to their non-smoking counterparts.22,24
A number of population-based studies have consistently shown that compared
with non-Hispanic Whites, non-white ethnicities, particularly non-Hispanic Blacks have
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high prevalence of obesity, insulin resistance and T2D.26 It is suggested that the ethnic
differences in these metabolic-related factors is partly explained by differences in
adiposity and body composition.1-3 Extensive research on ethnic differences in proinflammatory adipocytokines such as CRP and IL-6 linking adiposity, insulin resistance
and T2D have been conducted.27-29 Moreover, only a few epidemiological studies have
reported ethnic differences in leptin levels24,30-31 and such studies are yet to be conducted
among non-Hispanic Blacks. In addition, previous studies on leptin levels in individuals
with T2D are also controversial.32-34 Leptin levels were found to be lower in obese
individuals with T2D, whereas other data show increased or unchanged levels in these
individuals.
In the current study, we investigated; 1) ethnic variation of leptin levels in Haitian
and African Americans with and without T2D and 2) the association of leptin with BMI
and insulin resistance controlling for important confounders including diet and lifestyle
factors.

METHODS
Participants and Study Design
This was a cross-sectional study conducted in Haitian and African Americans
with (n= 197) and without (n = 216) T2D. The study protocol was approved by the
Institutional Review Board at Florida International University (FIU). Within a period of
one year, about 7550 letters were mailed to African Americans in South Florida, from the
Miami-Dade and Broward Counties to request their participation. The list of mailing
addresses for African Americans with and without T2D was purchased from the
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Knowledge Base Marketing, Inc., Richardson, TX, USA. Of the letters mailed, 4% (n =
256) of the participants responded. Due to unavailability of similar database of mailing
addresses for Haitian Americans, recruitment for this group was done through multiple
community based sources. These sources included local diabetes educators and
community health practitioners, and staff, faculty and students of FIU. In addition,
advertisements were placed in local Haitian supermarkets, churches, and restaurants and
announcements were aired on Creole radio stations. Respondents were interviewed on
phone. The purpose of the study was fully explained and the age (≥35 years), gender and
self-identified ethnicity (Haitian American or African American) were assessed. For
respondents who self-reported as having T2D, initial treatment modalities, duration of
diabetes and fasting plasma glucose (FPG) and glycated hemoglobin levels (A1C) were
obtained. Exclusion criteria included kidney failure, hepatitis, HIV and cancer. Eligible
participants were requested to enroll in the study at the Human Nutrition Laboratory at
FIU. Participants to enroll in the study were instructed to fast at least 8 hours prior to
their blood collection. Additionally, they were instructed to refrain from smoking and any
unusual exercise, but could drink only water. Written informed consent in English or
Creole was obtained from each participant after they understood the requirements on the
form. The laboratory results of twelve participants (8 Haitian Americans and 4 African
Americans) who reported not having T2D revealed high values for FPG and A1C and
were reclassified as having T2D. These individuals were referred to their physicians.
Participants (n = 103) with missing values and outliers for leptin, HOMA2-IR, serum
vitamin D {25(OH)D} and energy intake were excluded. A total of 413 participants, 197
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with T2D and 216 without T2D (213 Haitian and 200 African Americans) were included
in all data analysis.
Socio-demographic data
A standardized self-reported questionnaire was used to obtain information
regarding age, gender, smoking status, and medications used. Self-reported information
on ethnicity was confirmed during interview. Anthropometric measures were obtained at
the Human Nutrition Laboratory. Height and weight were measured with the SECA
balance scale (Seca Corp, Columbia, MD). Body mass index (BMI) was calculated as
weight in kg divided by height in m2.
Assessment of dietary intake
The validated and standardized Harvard semi-quantitative food frequency
questionnaire was used to obtain information on macro- and micro-nutrients from foods
and vitamins consumed. Participants self-reported average intake of specified quantities
of foods over the past year. Daily servings for food groups were calculated by totaling
frequency scores for all food items. The output of these calculations were used to obtain
the energy intake (kcal) of participants.
Blood collection and laboratory measurements
Twenty milliliters of venous blood was collected in a Vaccutainer Serum
Separator tubes by a trained and certified phlebotomist using standard methods, following
an 8-hour overnight fast. Blood samples were centrifuged at 2500 RPM for half an hour
after coagulation. The separated serum was aliquoted into 3 labeled plastic tubes. Two
were designated for analysis of glucose and vitamin D. The third aliquot was stored at -
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700C for subsequent analyses. Glucose levels were measured by hexokinase enzymatic
methods (Laboratory Corporation of America, FL, USA). Hemoglobin A1C percentages
were assayed in whole blood samples applying the Roche Tina Quant method
(Laboratory Corporation of America, FL, USA). Serum vitamin D (25(OH)D) levels
were determined with a commercial enzyme linked immunosorbent assay kit (ELISA)
from Immunodiagnostic Systems Limited (Scottsdale, AZ, U.S.).
Leptin levels in serum were measured at the Human Nutrition Laboratory at FIU
using ELISA developed with monoclonal antibody specific for leptin pre-coated onto a
microplate, according to manufacturer’s protocol (R&D Systems, Minneapolis, MN,
USA). Briefly, 100µl of Assay Diluent RD1-19 was added to each well followed by
100µl of standards, dilution buffer (blank) and diluted samples (100x – 10µl sample plus
990µl dilution buffer). After 2 hours of incubation at room temperature followed by
washing, 200µl of leptin conjugate was added and incubated with the bound leptin for an
hour. After a second washing step, 200 µl substrate solution was added and incubated for
half an hour to allow reaction with the residual conjugate. The reaction process was
stopped by addition of 50 µl of N sulfuric acid stop solution. The absorbance of the
resulting product was measured at 450nm with a spectrophotometer. A microplate reader
capable of creating a standard curve plotted the mean absorbance values against the leptin
concentrations of standards. The software used the standard curve to determine the
concentrations of the unknown diluted samples multiplied by the dilution factor to obtain
the actual amount of serum leptin. The sensitivity of the ELISA assay was 7.8 pg/ml and
the range was 7.8–1000 pg/ml (78–100000 pg/ml with dilution factor). The intraassay
and interassay coefficients of variation were both less than 10%.
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Calculation of insulin resistance (HOMA2-IR)
The Oxford University HOMA2 calculator was used to calculate insulin
resistance as previously described.35 The model determines insulin resistance (HOMA2IR) from paired fasting plasma glucose and radioimmunoassay insulin across a range of
1-2,200 pmol/l for insulin, and 1-25 mmol/l for glucose.
Data Analysis
All statistical analyses were conducted with SPSS version 21 (IBM Corporation,
Chicago, IL, USA). The Kolmogorov-Smirnov test was used to assess the normality of
the distribution of the data. The distributions of leptin and insulin resistance (HOMA2IR) were natural log-transformed to improve normality. All data analyses were separated
by gender because the mean serum leptin levels differed by gender in our sample.
Moreover, gender was an independent predictor of leptin levels in previous studies.23
Differences in mean values between ethnicity and diabetes status were compared by
Student’s t-test for continuous variables and χ2 tests for categorical variables. The
relationships between variables were analyzed by multiple linear regression using log
leptin as the dependent variable. The models were generated separately for diabetes status
and gender. Independent variables including BMI and HOMA2-IR as primary predictors,
age, ethnicity (Haitian American/African American), smoke status (yes/no), energy
intake, serum 25(OH)D, lipid lowering drugs (yes/no), nonsteroidal anti-inflammatory
drugs (NSAIDs) (yes/no) were forced into the model. For all analyses, a P-value of <0.05
was considered to be statistically significant.
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RESULTS
Of the 413 Haitian and African Americans with and without T2D, 49.9% were
males and 50.1% were females. The general demographic and health-related
characteristics of the study population by ethnicity are shown in Table 1. Compared with
Haitian Americans, African Americans were younger (P<0.05) and had a higher
percentage of smokers (P<0.001). African American females had higher mean BMI
(35.1±8.3 vs. 29.9±5.0, P<0.001), were more obese (P=0.003), had higher energy intake
(P=0.045), lower serum vitamin D levels (P=0.005), higher log HOMA2-IR (P=0.014)
and higher log leptin levels ((P=0.029) than did Haitian American females. While the
mean serum vitamin D levels (60.3±26.9 vs. 54.0±19.7, P=0.060) were higher in African
American males, although not significantly, the mean BMI (31.2±6.0 vs. 28.1±4.2,
P<0.001), obesity (P<0.001), energy intake (P<0.001), log HOMA2-IR (P=0.004) and
log leptin levels (P=0.001) were significantly lower in Haitian American males. With the
exception of significantly higher use of NSAIDs (P<0.001) among African American
females compared to Haitian American females, there was no significant ethnic
difference in the use of lipid lowering drugs and oral hypoglycemic medications between
males and females.
The general demographic and health-related characteristics of the study
population by diabetes status are shown in Table 2. BMI was significantly higher in
males and females with T2D compared to those without T2D (P<0.05), however, no
significant difference was observed for percentages of obese males and females with and
without T2D. Energy intake was significantly lower among males with T2D compared to
males without T2D (P<0.001), but no difference was seen in females. Although low

104

serum vitamin D levels were common in females with compared to those without T2D
(P=0.045), no significant difference was observed in males. As expected, the use of lipid
lowering drugs (P<0.001), NSAIDs (P<0.05) and oral hypoglycemic medications
(P<0.001) were significantly higher among males and females with T2D compared to
males and females without T2D. Both males and females with and without T2D had
similar tendencies to smoke. The mean log leptin and mean log HOMA2-IR were not
significantly different between males and females with and without T2D.
A test of the means by Student’s t-test showed a significant difference in serum
log leptin levels by males and females, obesity and ethnicity/diabetes status in the entire
sample (data not shown). Males had significantly lower mean log leptin levels as
compared to females (9.3±0.9 vs. 10.4±0.8, P<0.001). Obese individuals had significantly
higher mean log leptin levels compared with non-obese individuals (10.4±0.8 vs. 9.4±0.9,
P<0.001). In addition, Haitian Americans with T2D, contrary to our earlier hypothesis,
had lower mean log leptin levels compared to African Americans with T2D (9.6±1.2 vs.
10.1±0.8, P=0.001).
Tables 3 and 4 show the results of multiple linear regression analyses conducted
using serum log leptin levels as the dependent variable. In males with T2D, log levels of
leptin were predicted by ethnicity, age and BMI, whereas in males without T2D, BMI
and log HOMA2-IR were the major determinants. In females with T2D, changes in log
leptin levels were explained by BMI and log HOMA2-IR had a slight trend towards
significance. However, in females without T2D, BMI and smoking explained serum log
leptin levels, and ethnicity had a slight trend towards significance. Overall, BMI was the
strongest predictor of serum log leptin levels across all groups. These results reinforce
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existing evidence that serum log leptin levels in males are altered differently from those
of females. The differences in predictors of serum leptin levels between participants with
and without T2D may suggest T2D as an influential factor in our sample. Independent
variables for males with T2D and without T2D, females with T2D and without T2D
explained 44%, 61%, 18% and 33% of the variance of log leptin levels in separate
regression models, respectively. Energy intake, serum vitamin D and medications were
not significantly associated with log leptin levels.

DISCUSSION
In the present study, we evaluated serum leptin levels in Haitian and African
Americans with and without T2D. We observed significant differences in serum leptin
levels across ethnic groups by gender, but not with diabetes status by gender. Haitian
American males and females had lower serum leptin levels compared to African
American males and females. Among the diabetes groups, the nonsignificant difference
in serum leptin levels in participants with and without T2D is consistent with other
research.36 A number of factors may explain the nonsignificant difference observed:
firstly, advancing disease may cause continuing loss of the normal processes of leptin
regulation.36 Secondly, adiposity and gender are the main predictors of leptin levels in
both individuals with and without T2D. A difference in distribution of adipose tissue
accumulation, where subcutaneous fat has been shown to produce more leptin compared
to visceral fat.37-38 Individuals with T2D have been shown to have more visceral and less
subcutaneous adipocytes;38 although this was not determined in our study. Females with
T2D had lower leptin levels compared to females without T2D, whereas males with T2D
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had higher leptin levels than males without T2D, although nonsignificantly in both
instances. Thirdly, medications used in the treatment of T2D may reduce the leptin levels
in individuals with T2D. For instance, in a randomized clinical trial, metformin and
pioglitazone, two commonly used oral hypoglycemic medications reduced leptin levels in
individuals with newly diagnosed T2D.39 The lack of conclusive data regarding the levels
of leptin in individuals with T2D warrants further research among newly diagnosed drugfree T2D individuals.
As expected, in our study, we found that leptin was strongly associated with BMI,
a globally accepted surrogate of general adiposity, in all groups. Our sample was made up
of overweight (on the higher side) and obese individuals, thus the results observed is not
unexpected. Leptin is primarily an adipose-tissue derived peptide and the first identified
adipocytokine.13 Leptin regulates food behavior and energy expenditure and interacts
with inflammatory pathways and immune function.12,14,18-21 An autosomal recessive
mutation of the obese gene (ob) results in increased food intake and obesity.15 Thus,
increased levels of leptin signifying leptin resistance in obesity is the key feature of the
strong positive relationship between leptin with BMI and adipose mass. Leptin resistance
and the accumulation of adipose mass results in inflammatory responses in adipose
tissue. Leptin induces inflammation through key inflammatory pathways including JNK
and IKKβ.18 Moreover, with a similar structure to IL-6, leptin induces inflammatory
response through its proximal Janus kinase 2 (JAK2) signaling pathway and as such may
modulate C-reactive protein.19-21 Leptin also activates innate and adaptive immunity
which causes macrophages and monocytes to produce the pro-inflammatory
adipocytokines, IL-6 and TNF-α.20 Together, all these processes of leptin lead to insulin
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resistance in peripheral tissues. Various researchers have suggested that leptin may
actually be the link between obesity, insulin resistance and the development of T2D.22 In
our entire sample, obese individuals had significantly higher levels of leptin than nonobese individuals. The strong positive relationship of leptin with BMI found in our
sample is in agreement with those reported by previous studies for overweight/obese
participants with and without T2D.33-34,36,40
Type 2 diabetes is a disease of leptin and insulin-mediated signaling pathways.41
Leptin and insulin levels are directly interrelated with body weight and adipose mass.
Leptin attenuates insulin action and insulin signaling.18-21 However, the literature is
inconsistent regarding circulating leptin levels and insulin resistance. As mentioned,
gender difference may partially contribute to the discrepancies in our results. While some
studies have shown significance for the association between leptin and insulin resistance
in both males and females,42 others reported that leptin levels are associated with insulin
resistance independently of BMI only in males.43-44 Our study demonstrated that leptin
levels were significantly associated with insulin resistance (assessed by HOMA2-IR),
independently of BMI in males without T2D. However, in males with T2D and females
with and without T2D, only BMI was associated with levels of leptin after controlling for
confounders. Similarly, Hattori et al.45 reported that in a sample of 64 Japanese with and
without T2D, leptin levels were associated with insulin resistance independently of BMI
in both males with and without T2D. The authors stated that in females, only BMI was
associated with leptin levels. They concluded that the association between insulin
resistance and leptin levels in females is dependent on BMI since insulin resistance was
highly correlated with BMI in their sample. The reason of the differences by gender is
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proposed to be due to the regulation of leptin levels by the effect of sex hormones which
are triggered to control body weight.44,46 The nonsignificant association of HOMA2-IR
with leptin levels in males with T2D in our study, contrary to that observed by Hattori et
al.45 may be due to the use of diabetes medications in males with T2D. An alternative
explanation may be the nonsignificant difference in obesity, comparable serum vitamin D
levels and the higher dietary energy intake among males without T2D.
Leptin levels were significantly higher in African American men and there was a
slight trend toward significance (P=0.088) in African American women in regression
analysis. Higher proportions of BMI, higher HOMA2-IR, higher dietary energy intake
and lower serum levels of vitamin D among African American males and females
compared to Haitian American males and females may account for the observed higher
levels of leptin in African American males and females. Ethnic comparative studies have
demonstrated higher levels of leptin in ethnic populations with the highest prevalence of
metabolic risk factors.24,30-31 African Americans have consistently been shown to have
higher obesity and insulin resistance compared to non-Hispanic Whites and other
minorities including the non-Hispanic Black subgroup of Haitian Americans.26,47 The
greater influence of adiposity in ascertaining the levels of leptin in females, particularly
among African American women who had the highest proportion of obesity in the current
study may be applicable to the gender-based difference. Among African Americans,
particularly African American women, obesity is well accepted and their view of an ideal
body weight has been significantly higher compared to non-Hispanic Whites.48-49
Although data is lacking in Haitian Americans, available evidence shows that they are
less obese and moreover have fewer metabolic abnormalities compared to African
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Americans.47 The observed ethnic subgroup differences in the risk factors may also
reflect an interplay of behavioral and lifestyle, genetic and acculturation factors which
warrant further investigations.
Regression analyses revealed that socio-demographic and lifestyle factors such as
age and smoking were positively and inversely associated with leptin levels in men with
T2D and women without T2D, respectively. Similar to the study conducted by Schautz et
al.50 leptin levels were increased as an individual ages. A possible explanation may be the
age-related metabolic decline which alters fat distribution, obesity and insulin resistance.
The inverse association between smoking and leptin levels may be due to a possibility of
nicotine to increase sensitivity of insulin dependent tissues to leptin.22,24
The cross-sectional design of our study limits us from establishing causality
between ethnicity, obesity, insulin resistance and T2D with leptin levels. In addition,
genetic variation and differences in lifestyle, environmental and acculturation factors
which have the possibility to alter leptin levels between Haitian and African Americans
were not determined in this study. Although this study used HOMA2-IR an estimate of
insulin resistance rather than the gold standard of hyperinsulinemic-euglycemic clamp,
the HOMA2-IR has been used in several cross-sectional studies and has been shown to be
a reliable surrogate in determining measures of insulin resistance.51 The semiconvenience nature of our sample is not representative of Haitian and African Americans
and thus, limits generalizability to the larger population.
The strength of our study is that we are the first to report gender differences in
leptin levels in two non-Hispanic Black ethnic subgroups. Our results show that serum
leptin levels are influenced differently in women compared to men. While the
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relationship between metabolic risk factors and leptin levels in African Americans have
been extensively reported in the literature, however, information for Haitian Americans is
lacking. Thus, this study has not only generated data on this relationship in Haitian
Americans, but also highlights the need to target these non-Hispanic Black ethnic
subgroups separately considering the profound differences in metabolic risk factors.

CONCLUSION
In conclusion, our results showed that in males without T2D, both BMI and
HOMA2-IR were independently associated with leptin levels while in males with T2D
and females with and without T2D, only BMI one of the primary independent variables
was associated with leptin levels. Further, contrary to our earlier hypothesis, we found
leptin levels to be lower in Haitian Americans with T2D irrespective of gender compared
to African Americans with T2D. The lower leptin levels in Haitian Americans may be
due to favorable metabolic profile including lower obesity and insulin resistance. The
ethnic differences may also be attributable to genetic variation and differences in
lifestyle, environmental and acculturation factors which may affect risk of disease. Future
studies should focus on the association of these factors with leptin levels in the two
subethnic groups. In addition, these findings may help identify individuals at risk for T2D
across adiposity level and make an important contribution in designing ethnic centered
interventions to prevent T2D in this population.

111

REFERENCES:
1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in
the distribution of body mass index among US adults, 1999-2010. JAMA.
2012;307(5):491-497.
2. Centers for Disease Control and Prevention. Overweight and Obesity. Adult
Obesity Facts 2014. Available at: http://www.cdc.gov/obesity/data/adult.html.
Accessed on August 18, 2014.
3. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult
obesity in the United States, 2011-2012. JAMA. 2014;311(8):806-814.
4. Centers for Disease Control and Prevention. Early Release of Selected Estimates
Based on Data From the 2007 National Health Interview Survey. Available at:
http://www.cdc.gov/nchs/data/nhis/earlyrelease/200712_06.pdf. Accessed on
August 18, 2014.
5. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the
United States, 2000. JAMA. 2004;291(10):1238-1245.
6. Haslam DW, James WP. Obesity. Lancet. 2005;366(9492):1197-1209.
7. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest.
2005;115(5):1111-1119.
8. Narayan KM, Gregg EW, Fagot-Campagna A, Engelgau MM, Vinicor F.
Diabetes—a common, growing, serious, costly, and potentially preventable public
health problem. Diabetes Res Clin Pract. 2000;50 Suppl 2:S77-84.
9. American Diabetes Association. National Diabetes Statistics Report, 2014.
Statistics About Diabetes. Available at: http://www.diabetes.org/diabetesbasics/statistics/. Accessed on August 18, 2014.
10. Bertoni AG, Burke GL, Owusu JA, Carnethon MR, Vaidya D, Barr RG, Jenny
NS, Ouyang P, Rotter JI. Inflammation and the incidence of type 2 diabetes: the
Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2010;33(4):804810.
11. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein,
interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA.
2001;286(3):327-334.
12. Mantzoros CS. The role of leptin in human obesity and disease: a review of
current evidence. Ann Intern Med. 1999;130(8):671-680.
112

13. Zhang X, Zhang G, Zhang H, Karin M, Bai H, Cai D. Hypothalamic IKKbeta/NFkappaB and ER stress link overnutrition to energy imbalance and obesity. Cell.
2008;135(1):61-73.
14. Blüher S, Mantzoros CS. Leptin in humans: lessons from translational research.
Am J Clin Nutr. 2009;89(3):991S-997S.
15. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals.
Nature. 1998;395(6704):763-770.
16. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional
cloning of the mouse obese gene and its human homologue. Nature.
1994;372(6505):425-432.
17. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone
RL, Burley SK, Friedman JM. Weight-reducing effects of the plasma protein
encoded by the obese gene. Science. 1995;269(5223):543-546.
18. Mahabir S, Baer D, Johnson LL, Roth M, Campbell W, Clevidence B, Taylor PR.
Body Mass Index, percent body fat, and regional body fat distribution in relation
to leptin concentrations in healthy, non-smoking postmenopausal women in a
feeding study. Nutr J. 2007;6:3.
19. Lam QL, Lu L. Role of leptin in immunity. Cell Mol Immunol. 2007;4(1):1-13.
20. Gainsford T, Willson TA, Metcalf D, Handman E, McFarlane C, Ng A, Nicola
NA, Alexander WS, Hilton DJ. Leptin can induce proliferation, differentiation,
and functional activation of hemopoietic cells. Proc Natl Acad Sci.
1996;93(25):14564-14568.
21. Chen K, Li F, Li J, Cai H, Strom S, Bisello A, Kelley DE, Friedman-Einat M,
Skibinski GA, McCrory MA, Szalai AJ, Zhao AZ. Induction of leptin resistance
through direct interaction of C-reactive protein with leptin. Nat Med.
2006;12(4):425-432.
22. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR,
Ohannesian JP, Marco CC, McKee LJ, Bauer TL, et al. Serum immunoreactiveleptin concentrations in normal-weight and obese humans. N Engl J Med.
1996;334(5):292-295.
23. Hickey MS, Israel RG, Gardiner SN, Considine RV, McCammon MR, Tyndall
GL, Houmard JA, Marks RH, Caro JF. Gender differences in serum leptin levels
in humans. Biochem Mol Med. 1996;59(1):1-6.

113

24. Wei M, Stern MP, Haffner SM. Serum leptin levels in Mexican Americans and
non-Hispanic whites: association with body mass index and cigarette smoking.
Ann Epidemiol. 1997;7(2):81-86.
25. Belenchia AM, Tosh AK, Hillman LS, Peterson CA. Correcting vitamin D
insufficiency improves insulin sensitivity in obese adolescents: a randomized
controlled trial. Am J Clin Nutr. 2013;97(4):774-781.
26. Dagogo-Jack S. Ethnic disparities in type 2 diabetes: pathophysiology and
implications for prevention and management. J Natl Med Assoc.
2003;95(9):774,779-789.
27. Bertoni AG, Burke GL, Owusu JA, Carnethon MR, Vaidya D, Barr RG, Jenny
NS, Ouyang P, Rotter JI. Inflammation and the incidence of type 2 diabetes: the
Multi-Ethnic Study of Atherosclerosis (MESA). Diabetes Care. 2010;33(4):804810.
28. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A,
Hoogeveen R, Folsom AR, Heiss G; Atherosclerosis Risk in Communities Study.
Low-grade systemic inflammation and the development of type 2 diabetes: the
atherosclerosis risk in communities study. Diabetes. 2003;52(7):1799-1805.
29. Paalani M, Lee JW, Haddad E, Tonstad S. Determinants of inflammatory markers
in a bi-ethnic population. Ethn Dis. 2011;21(2):142-149.
30. Zimmet P, Hodge A, Nicolson M, Staten M, de Courten M, Moore J, Morawiecki
A, Lubina J, Collier G, Alberti G, Dowse G. Serum leptin concentration, obesity,
and insulin resistance in Western Samoans: cross sectional study. BMJ.
1996;313(7063):965-969.
31. Haffner SM, Stern MP, Miettinen H, Wei M, Gingerich RL. Leptin concentrations
in diabetic and nondiabetic Mexican-Americans. Diabetes. 1996;45(6):822-824.
32. Al-Daghri N, Al-Rubean K, Bartlett WA, Al-Attas O, Jones AF, Kumar S. Serum
leptin is elevated in Saudi Arabian patients with metabolic syndrome and
coronary artery disease. Diabet Med. 2003;20(10):832-837.
33. Abdelgadir M, Elbagir M, Eltom M, Berne C, Ahrén B. Reduced leptin
concentrations in subjects with type 2 diabetes mellitus in Sudan. Metabolism.
2002;51(3):304-306.
34. Ozata M, Gungor D, Turan M, Ozisik G, Bingol N, Ozgurtas T, Ozdemir IC.
Improved glycemic control increases fasting plasma acylation-stimulating protein
and decreases leptin concentrations in type II diabetic subjects. J Clin Endocrinol
Metab. 2001;86(8):3659-3664.

114

35. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling.
Diabetes Care. 2004;27(6):1487-1495.
36. Tatti P, Masselli L, Buonanno A, Di Mauro P, Strollo F. Leptin levels in diabetic
and nondiabetic subjects. Endocrine. 2001;15(3):305-308.
37. Van Gaal LF, Wauters MA, Mertens IL, Considine RV, De Leeuw IH. Clinical
endocrinology of human leptin. Int J Obes Relat Metab Disord. 1999;23 Suppl
1:29-36.
38. Lefebvre AM, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, Vidal H.
Depot-specific differences in adipose tissue gene expression in lean and obese
subjects. Diabetes. 1998;47(1):98-103.
39. Esteghamati A, Noshad S, Rabizadeh S, Ghavami M, Zandieh A, Nakhjavani M.
Comparative effects of metformin and pioglitazone on omentin and leptin
concentrations in patients with newly diagnosed diabetes: a randomized clinical
trial. Regul Pept. 2013;182:1-6.
40. Zuo H, Shi Z, Yuan B, Dai Y, Wu G, Hussain A. Association between serum
leptin concentrations and insulin resistance: a population-based study from China.
PLoS One. 2013;8(1):e54615.
41. Kulkarni RN, Wang ZL, Wang RM, Hurley JD, Smith DM, Ghatei MA, Withers
DJ, Gardiner JV, Bailey CJ, Bloom SR. Leptin rapidly suppresses insulin release
from insulinoma cells, rat and human islets and, in vivo, in mice. J Clin Invest.
1997;100(11):2729-2736.
42. de Courten M, Zimmet P, Hodge A, Collins V, Nicolson M, Staten M, Dowse G,
Alberti KG. Hyperleptinaemia: the missing link in the, metabolic syndrome?
Diabet Med. 1997;14(3):200-208.
43. Vettor R, De Pergola G, Pagano C, Englaro P, Laudadio E, Giorgino F, Blum
WF, Giorgino R, Federspil G. Gender differences in serum leptin in obese people:
relationships with testosterone, body fat distribution and insulin sensitivity. Eur J
Clin Invest. 1997;27(12):1016-1024.
44. Kennedy A, Gettys TW, Watson P, Wallace P, Ganaway E, Pan Q, Garvey WT.
The metabolic significance of leptin in humans: gender-based differences in
relationship to adiposity, insulin sensitivity, and energy expenditure. J Clin
Endocrinol Metab. 1997;82(4):1293-1300.
45. Hattori A, Uemura K, Miura H, Ueda M, Tamaya N, Iwata F, Muraguchi M,
Ohmoto Y, Iguchi A. Gender-related difference in relationship between insulin

115

resistance and serum leptin level in Japanese type 2 diabetic and non-diabetic
subjects. Endocr J. 2000;47(5):615-621.
46. Rosenbaum M, Nicolson M, Hirsch J, Heymsfield SB, Gallagher D, Chu F, Leibel
RL. Effects of gender, body composition, and menopause on plasma
concentrations of leptin. J Clin Endocrinol Metab. 1996;81(9):3424-3427.
47. Huffman F, Vallasciani M, Vaccaro J, Exebio J, Zarini G, Nayer A, Ajabshir, S.
The association of depression and perceived stress with beta cell function between
African and Haitian Americans with and without type 2 diabetes. J of Diabetes
Mellit. 2013;3:236-243.
48. Latner JD, Stunkard AJ, Wilson GT. Stigmatized students: age, sex, and ethnicity
effects in the stigmatization of obesity. Obes Res. 2005;13(7):1226-1231.
49. Becker DM, Yanek LR, Koffman DM, Bronner YC. Body image preferences
among urban African Americans and whites from low income communities. Ethn
Dis. 1999;9(3):377-386.
50. Schautz B, Later W, Heller M, Peters A, Müller MJ, Bosy-Westphal A. Impact of
age on leptin and adiponectin independent of adiposity. Br J Nutr.
2012;108(2):363-370.
51. Exebio JC, Ajabshir S, Zarini GG, Vaccaro J, Huffman FG. Use of Homeostatic
Model Assessment Indexes for the Identification of Metabolic Syndrome and
Insulin Resistance among Cuban-Americans: A Cross Sectional Study. Br J Med
Med Res. 2014;4(29): 4824-4833.

116

TABLE 1. Characteristics of the Participants by Sex and Ethnicity
Variables

Male
Haitian
African
American
American
(n = 104)
(n = 102)
54.9±9.8
51.9±7.8

Pvalue
0.014
0.582

Age (years)
Diabetes status
With T2D n (%)
47(45.2)
50(49.0)
Without T2D n (%)
57(54.8)
52(51.0)
2
BMI (kg/m )
28.1±4.2
31.2±6.0
<0.001
Obese (BMI ≥30 kg/m2)
<0.001
Yes n (%)
32(30.8)
58(56.9)
No n (%)
72(69.2)
44(43.1)
Smoke n (%)
11(10.6)
51(50.0)
<0.001
Energy intake (kcal/d)
1844.0±1161.3 2759.0±1846.1 <0.001
25(OH)D (nmol/L)
54.0±19.7
60.3±26.9
0.060
Lipid lowering drugs n (%)
22(21.2)
27(26.5)
0.370
NSAIDs n (%)
26(25.0)
33(32.4)
0.243
Oral hypoglycemic meds n (%) 42(40.4)
35(34.3)
0.368
A1C (%)
7.4±2.4
6.7±1.7
0.028
FPG (mmol/L)
130.2±58.6
122.7±53.5
0.343
Insulin (µIU/mL)
8.8±5.1
12.9±11.1
0.001
log HOMA2-IR
0.1±0.5
0.3±0.7
0.004
log Leptin (pg/mL)
9.1±0.9
9.6±0.9
0.001

Female
Haitian
African
American
American
(n = 109)
(n = 98)
56.9±10.9
53.8±10.8
53(48.6)
56(51.4)
29.9±5.0
56(51.4)
53(48.6)
1(0.9)
1821.3±1074.4
56.2±18.3
25(22.9)
26(23.9)
48(44.0)
7.1±1.9
125.6±48.1
10.8±7.1
0.2±0.5
10.3±0.9

47(48.0)
51(52.0)
35.1±8.3

<0.001
0.003

70(71.4)
28(28.6)
30(30.6)
<0.001
2201.7±1561.6 0.045
48.6±19.8
0.005
32(32.7)
0.118
46(46.9)
<0.001
40(40.8)
0.640
6.8±1.7
0.294
121.8±55.0
0.600
13.9±9.8
0.011
0.5±0.
0.014
10.7±0.7
0.029

Data were expressed as mean ± SD unless otherwise indicated. Abbreviations: T2D = type 2 diabetes; BMI = body mass index;
NSAIDs = nonsteroidal anti-inflammatory drugs; A1C= hemoglobin A1C; FPG = fasting plasma glucose; HOMA2-IR = homeostasis
model assessment version 2 of insulin resistance. P-value is considered significant at <0.05.

117

Pvalue
0.043
0.924

TABLE 2. Characteristics of the Participants by Sex and Diabetes Status
Variables

Male
With
Without
T2D
T2D
(n = 97)
(n = 109)
55.9±9.1
51.1±8.2

Age (years)
Ethnicity
HA n (%)
47(48.5)
AA n (%)
50(51.5)
2
BMI (kg/m )
30.4±5.6
Obese (BMI ≥30 kg/m2)
Yes n (%)
49(50.5)
No n (%)
48(49.5)
Smoke n (%)
27(27.8)
Energy intake (kcal/d)
1885.65±1254.8
25(OH)D (nmol/L)
55.8±22.9
Lipid lowering drugs n (%)
38(39.2)
NSAIDs n (%)
37(38.1)
Oral hypoglycemic meds n (%) 77(79.4)
A1C (%)
8.2±2.5
FPG (mmol/L)
154.5±67.6
Insulin (µIU/mL)
10.6±8.9
log HOMA2-IR
0.2±0.6
log Leptin (pg/mL)
9.4±0.9

57(52.3)
52(47.7)
28.9±5.1
41(37.6)
68(62.4)
35(32.1)
2663.2±1784.9
58.3±24.5
11(10.1)
22(20.2)
6.0±0.8
101.6±24.2
11.1±8.8
0.2±0.6
9.3±0.8

Pvalue
<0.001
0.582

0.043
0.062
0.504
<0.001
0.445
<0.001
0.004
<0.001
<0.001
0.688
0.599
0.532

Female
With
Without
T2D
T2D
(n = 100)
(n = 107)
57.1±11.0
53.9±10.7
53(53.0)
47(47.0)
33.9±8.2
67(67.0)
33(33.0)
14(14.0)
1826.9±1147.8
49.8±21.5
44(44.0)
44(44.0)
88(88.0)
7.9±2.2
148.1±61.0
12.7±9.4
0.4±0.6
10.4±0.9

56(52.3)
51(47.7)
30.9±5.9

0.004
0.081

59(55.1)
48(44.9)
17(15.9)
0.704
2164.4±1480.6
0.070
55.2±16.9
0.045
13(12.1)
<0.001
28(26.2)
0.007
6.1±0.7
<0.001
101.0±23.9
<0.001
11.8±7.8
0.429
0.3±0.6
0.115
10.5±0.7
0.302

Data were expressed as mean ± SD unless otherwise indicated. Abbreviations: T2D = type 2 diabetes; HA = Haitian Americans;
AA = African Americans; BMI = body mass index; NSAIDs = nonsteroidal anti-inflammatory drugs; A1C = hemoglobin A1C;
FPG = fasting plasma glucose; HOMA2-IR = homeostasis model assessment version 2 of insulin resistance. P-value is
considered significant at <0.05.
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Pvalue
0.035
0.924

TABLE 3. Relationship of Leptin with BMI and HOMA2-IR in Participants with T2D – Multiple Linear
Regression Analysis
Male (n = 97)
Variables
BMI
HOMA2-IR
Ethnicity
Age
Smoke
Energy intake
25(OH)D
Lipid lowering drugs
NSAIDs

Female (n= 100)

B

SE

P-value

B

SE

P-value

0.113
-0.217
0.548
0.035
-0.093
0.000
-0.005
0.334
-0.235

0.017
0.134
0.212
0.010
0.200
0.001
0.003
0.168
0.172

<0.001
0.109
0.011
0.001
0.644
0.178
0.133
0.050
0.176

0.055
-0.268
-0.006
-0.002
0.077
0.000
0.001
0.079
0.104

0.013
0.142
0.206
0.008
0.255
0.001
0.004
0.177
0.183

<0.001
0.063
0.977
0.838
0.762
0.986
0.948
0.656
0.572

Abbreviations: BMI = body mass index; HOMA2-IR = homeostasis model assessment version 2 of insulin resistance; NSAIDs = nonsteroidal
anti-inflammatory drugs; B = unstandardized coefficients; SE = standard error. Leptin and HOMA2-IR were natural log transformed.
P-value is considered significant at <0.05.
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TABLE 4. Relationship of Leptin with BMI and HOMA2-IR in Participants without T2D – Multiple Linear
Regression Analysis
Male (n = 109)
Variables
BMI
HOMA2-IR
Ethnicity
Age
Smoke
Energy intake
25(OH)D
Lipid lowering drugs
NSAIDs

B
0.111
0.240
0.125
0.012
-0.186
0.000
- 0.002
0.130
0.105

SE
0.012
0.097
0.127
0.007
0.132
0.001
0.002
0.200
0.152

Female (n= 107)

P-value
<0.001
0.015
0.326
0.110
0.162
0.311
0.448
0.516
0.489

B

SE

P-value

0.058
-0.032
0.225
0.005
-0.712
0.000
0.003
0.108
-0.048

0.011
0.118
0.131
0.005
0.184
0.001
0.003
0.189
0.140

<0.001
0.786
0.088
0.397
<0.001
0.239
0.440
0.569
0.732

Abbreviations: BMI = body mass index; HOMA2-IR = homeostasis model assessment version 2 of insulin resistance; NSAIDs = nonsteroidal
anti-inflammatory drugs; B = unstandardized coefficients; SE = standard error. Leptin and HOMA2-IR were natural log transformed.
P-value is considered significant at <0.05.
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CHAPTER VI: SUMMARY AND FUTURE RESEARCH
The overall primary purpose of the current study was to examine the relationship
of adipocytokines with metabolic syndrome (MetS), anthropometric and HOMA2
measures by ethnicity and diabetes status in Haitian and African Americans. The
involvement of adipocytokines in inflammatory response and metabolic regulation, the
association of adipocytokines with adiposity and consequently development of MetS and
T2D, and the high susceptibility of non-Hispanic Blacks for inflammation illustrated in
the literature initiated this research assessing the effects of adipocytokines in processes
leading to metabolic disorders such as T2D.
The altered levels of pro- and anti-inflammatory adipocytokines due to constant
stimulation of the innate immune system has been suggested as the basis for chronic lowgrade inflammation. It is proposed that this alteration is pronounced with increasing
adiposity as seen in obese individuals and restored with weight loss. Although the
mechanisms accountable for adipocytokines in metabolic disorders are not completely
elucidated, it is thought that altered adipocytokine levels which favor pro-inflammatory
adipocytokines impair insulin secretion in pancreatic β cells, in addition to perturbation
of insulin signaling pathways leading to development of T2D. The measurement of
adipocytokine levels allowed an assessment of inflammation, and their relationship to
obesity, insulin resistance, MetS and T2D. The dissertation comprised of three studies
that were built on data from the parent study.
Explorations of the associations of the pro-inflammatory adipocytokines IL-6 and
CRP with MetS and its components showed that CRP, but not IL-6 was positively
associated with MetS after adjusting for important confounders. This partially supported
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our hypothesis that higher levels of IL-6 and CRP will be associated with having MetS.
Notwithstanding, the current findings support others that have shown the uniqueness of
CRP as an established and strong predictor of MetS. A lack of association between IL-6
and MetS has been reported in previous studies. However, the inverse direction found in
our study may be due to the tight connection of IL-6 with adiposity. Where, lipid
lowering drugs may have caused a decrease in adiposity and dampened the association of
IL-6 with MetS. Our earlier hypothesis that Haitian Americans with T2D will have higher
IL-6 and CRP levels compared to African Americans was found to be the reverse. Higher
levels of both IL-6 and CRP were associated with African American ethnicity, however
there was no association with diabetes status. Favorable metabolic factors such as lower
BMI, waist circumference, insulin resistance and others including acculturation, genetic
and lifestyle factors in Haitian Americans may have contributed to these findings.
Findings of the relationship between novel adipocytokines, chemerin and omentin
with insulin sensitivity, ethnicity and diabetes status showed significant ethnic
differences for chemerin between ethnic groups, with Haitian Americans having the
lowest chemerin levels compared to African Americans. Omentin levels did not differ
significantly between Haitian and African Americans. Moreover, there was no significant
difference in either chemerin or omentin levels by diabetes status. However, analyses of
these adipocytokines stratified by both ethnicity and diabetes status showed that Haitian
Americans with T2D had lower chemerin and higher omentin levels than African
Americans with T2D. Linear regression models generated with chemerin and omentin as
separate dependent variables showed that chemerin was inversely associated with insulin
sensitivity and positively associated with African American ethnicity and diabetes status.
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Omentin on the other hand was positively associated with insulin sensitivity and
negatively associated with being African American and diabetes status. Apart from a
most likely explanation of Haitian Americans possessing advantageous characteristics to
have accounted for the results observed, the intake of medications by a majority of our
participants may have also affected the study outcome despite controlling for medication
use.
The assessment of the relationship between leptin with BMI and insulin resistance
by ethnicity and diabetes status was also conducted. Since leptin levels differed by gender
in our study, analysis were stratified in line with this difference. Leptin levels were not
statistically different between males and females, regardless of diabetes status. However,
with further classification by ethnicity and diabetes status, both Haitian American males
and females were found to have lower leptin levels compared to African Americans.
Additionally BMI and insulin resistance were predictors of higher leptin levels only in
males without T2D.
The novel finding of our study is the differences shown in chemerin and omentin
levels and their association with metabolic parameters in two non-Hispanic Black ethnic
subgroups which has previously not being studied. Other strengths of our study include
the use of a gender-balanced cohort and for the first time has generated data on
established and novel adipocytokines particularly in Haitian Americans, a group
undersampled in diabetes studies.
Several limitations of this research are important to mention. Failure of our study
to support some of the hypotheses stated is again believed to be due to the high use of
medications that have been shown to influence adipocytokines levels by majority of our
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study subjects. Moreover, we could not control for relevant lifestyle factors such as
physical activity and detailed dietary factors which also affect adipocytokine levels. The
cross-sectional design of this study did not allow the determination of temporal and
causal associations. In addition, the study population is a semi-convenience sample and
may therefore not be representative of Haitian Americans and African Americans living
in South Florida. As a result, generalizability to the larger population may be limited. The
use of surrogate markers such as serum IL-6 concentrations in lieu of IL-6 receptor and
HOMA-IR instead of the hyperinsulinemic-euglycemic clamp may have also influenced
the results of this study.
The current study reveals important differences between Haitian and African
Americans and further establishes a need for future research to consider these two nonHispanic Black ethnic subgroups as unique in order to design effective ethnic-focused
interventions to reduce the disparities and the high incidence of T2D and its outcomes. A
better understanding of the role of adipocytokines in the regulation of glucose and lipid
homeostasis through insulin secretion and signaling is needed. To fully understand the
ethnic specific effect on the role of adipocytokines, further investigation among Haitian
and African Americans should be performed.
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